Health Care Guideline
Antithrombotic Therapy Supplement

How to cite this document:

Copies of this ICSI Health Care Guideline may be distributed by any organization to the organization’s employees but, except as provided below, may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc. If the organization is a legally constituted medical group, the ICSI Health Care Guideline may be used by the medical group in any of the following ways:

- copies may be provided to anyone involved in the medical group’s process for developing and implementing clinical guidelines;
- the ICSI Health Care Guideline may be adopted or adapted for use within the medical group only, provided that ICSI receives appropriate attribution on all written or electronic documents and
- copies may be provided to patients and the clinicians who manage their care, if the ICSI Health Care Guideline is incorporated into the medical group’s clinical guideline program.

All other copyright rights in this ICSI Health Care Guideline are reserved by the Institute for Clinical Systems Improvement. The Institute for Clinical Systems Improvement assumes no liability for any adaptations or revisions or modifications made to this ICSI Health Care Guideline.
### Index of Annotations

<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Warfarin</td>
</tr>
<tr>
<td>1.0</td>
<td>Introduction, Warfarin</td>
</tr>
<tr>
<td>1.1</td>
<td>Adverse Effects, Warfarin</td>
</tr>
<tr>
<td>1.2</td>
<td>Contraindications, Warfarin</td>
</tr>
<tr>
<td>1.3</td>
<td>Precautions, Warfarin</td>
</tr>
<tr>
<td>1.4</td>
<td>Pregnancy, Warfarin – High Risk</td>
</tr>
<tr>
<td>1.5</td>
<td>Breastfeeding, Warfarin</td>
</tr>
<tr>
<td>1.6</td>
<td>Dosing, Warfarin</td>
</tr>
<tr>
<td>1.7</td>
<td>Monitoring, Warfarin</td>
</tr>
<tr>
<td>1.8</td>
<td>Correction of Supratherapeutic Anticoagulation/Reversal, Warfarin</td>
</tr>
<tr>
<td>1.9</td>
<td>Patient Education, Warfarin</td>
</tr>
<tr>
<td>2.</td>
<td>Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH)</td>
</tr>
<tr>
<td>2.0</td>
<td>Introduction, UFH and LMWH</td>
</tr>
<tr>
<td>2.1</td>
<td>Adverse Effects, Including Heparin-Induced Thrombocytopenia, of UFH and LMWH</td>
</tr>
<tr>
<td>2.2</td>
<td>Contraindications, UFH and LMWH</td>
</tr>
<tr>
<td>2.3</td>
<td>Precautions, UFH and LMWH</td>
</tr>
<tr>
<td>2.4</td>
<td>Pregnancy, UFH and LMWH</td>
</tr>
<tr>
<td>2.5</td>
<td>Breastfeeding, UFH and LMWH</td>
</tr>
<tr>
<td>2.6</td>
<td>Dosing</td>
</tr>
<tr>
<td>2.61</td>
<td>UFH Dosing</td>
</tr>
<tr>
<td>2.62</td>
<td>LMWH Dosing</td>
</tr>
<tr>
<td>2.7</td>
<td>Monitoring</td>
</tr>
<tr>
<td>2.71</td>
<td>UFH Monitoring</td>
</tr>
<tr>
<td>2.72</td>
<td>LMWH Monitoring</td>
</tr>
<tr>
<td>2.8</td>
<td>Correction of Supratherapeutic Anticoagulation/Reversal</td>
</tr>
<tr>
<td>2.81</td>
<td>UFH, Correction of Supratherapeutic Anticoagulation/Reversal</td>
</tr>
<tr>
<td>2.82</td>
<td>LMWH, Correction of Supratherapeutic Anticoagulation/Reversal</td>
</tr>
<tr>
<td>2.9</td>
<td>Patient Education</td>
</tr>
<tr>
<td>2.91</td>
<td>UFH, Patient Education</td>
</tr>
<tr>
<td>2.92</td>
<td>LMWH, Patient Education</td>
</tr>
<tr>
<td>3.</td>
<td>Synthetic Pentasaccharide (Fondaparinux)</td>
</tr>
<tr>
<td>3.0</td>
<td>Introduction, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.1</td>
<td>Adverse Effects, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.2</td>
<td>Contraindications, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.3</td>
<td>Precautions, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.4</td>
<td>Pregnancy, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.5</td>
<td>Breastfeeding, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.6</td>
<td>Dosing, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.7</td>
<td>Monitoring, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.8</td>
<td>Correction of Supratherapeutic Anticoagulation/Reversal, Synthetic Pentasaccharide</td>
</tr>
<tr>
<td>3.9</td>
<td>Patient Education, Synthetic Pentasaccharide</td>
</tr>
</tbody>
</table>

*Text in blue in this guideline indicates a linked corresponding annotation.*

**Return to Table of Contents**

www.icsi.org

Copyright © 2013 by Institute for Clinical Systems Improvement
## Index of Annotations

### 4. Direct Thrombin Inhibitors (DTI)

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.0</td>
<td>Introduction, DTI</td>
</tr>
<tr>
<td>4.0a</td>
<td>Key Considerations for Dabigatran</td>
</tr>
<tr>
<td>4.1a</td>
<td>Adverse Effects, Dabigatran</td>
</tr>
<tr>
<td>4.2a</td>
<td>Contraindications, Dabigatran</td>
</tr>
<tr>
<td>4.3a</td>
<td>Precautions, Dabigatran</td>
</tr>
<tr>
<td>4.4a</td>
<td>Pregnancy, Dabigatran</td>
</tr>
<tr>
<td>4.5a</td>
<td>Breastfeeding, Dabigatran</td>
</tr>
<tr>
<td>4.6a</td>
<td>Dosing, Dabigatran</td>
</tr>
<tr>
<td>4.7a</td>
<td>Monitoring and Effect on Laboratory Testing, Dabigatran</td>
</tr>
<tr>
<td>4.8a</td>
<td>Correction of Supratherapeutic Anticoagulation/Reversal, Dabigatran</td>
</tr>
<tr>
<td>4.9a</td>
<td>Patient Education, Dabigatran</td>
</tr>
<tr>
<td>4.0b</td>
<td>Key Considerations for Parenteral DTIs</td>
</tr>
<tr>
<td>4.1b</td>
<td>Adverse Effects, Parenteral DTI</td>
</tr>
<tr>
<td>4.2b</td>
<td>Contraindications, Parenteral DTI</td>
</tr>
<tr>
<td>4.3b</td>
<td>Precautions, Parenteral DTI</td>
</tr>
<tr>
<td>4.4b</td>
<td>Pregnancy, Parenteral DTI</td>
</tr>
<tr>
<td>4.5b</td>
<td>Breastfeeding, Parenteral DTI</td>
</tr>
<tr>
<td>4.6b</td>
<td>Dosing, Parenteral DTI</td>
</tr>
<tr>
<td>4.7b</td>
<td>Monitoring, Parenteral DTI</td>
</tr>
<tr>
<td>4.8b</td>
<td>Correction of Supratherapeutic Anticoagulation/Reversal, Parenteral DTI</td>
</tr>
<tr>
<td>4.9b</td>
<td>Patient Education, Parenteral DTI</td>
</tr>
</tbody>
</table>

### 5. Oral Factor Xa Inhibitors

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.0</td>
<td>Key Considerations for Rivaroxaban</td>
</tr>
<tr>
<td>5.1</td>
<td>Adverse Effects, Rivaroxaban</td>
</tr>
<tr>
<td>5.2</td>
<td>Contraindications, Rivaroxaban</td>
</tr>
<tr>
<td>5.3</td>
<td>Precautions, Rivaroxaban</td>
</tr>
<tr>
<td>5.4</td>
<td>Pregnancy, Rivaroxaban</td>
</tr>
<tr>
<td>5.5</td>
<td>Breastfeeding, Rivaroxaban</td>
</tr>
<tr>
<td>5.6</td>
<td>Dosing, Rivaroxaban</td>
</tr>
<tr>
<td>5.7</td>
<td>Monitoring and Effect on Laboratory Testing, Rivaroxaban</td>
</tr>
<tr>
<td>5.8</td>
<td>Correction of Supratherapeutic Anticoagulation/Reversal, Rivaroxaban</td>
</tr>
<tr>
<td>5.9</td>
<td>Patient Education, Rivaroxaban</td>
</tr>
</tbody>
</table>

*Return to Table of Contents*
6. **Antiplatelet Agents**

<table>
<thead>
<tr>
<th>6.0</th>
<th>Introduction, Antiplatelet Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.0a</td>
<td>Key Considerations for Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.1a</td>
<td>Adverse Effects, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.2a</td>
<td>Contraindications, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.3a</td>
<td>Precautions, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.4a</td>
<td>Pregnancy, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.5a</td>
<td>Breastfeeding, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.6a</td>
<td>Dosing, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.7a</td>
<td>Monitoring, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.8a</td>
<td>Correction of Supratherapeutic Anticoagulation/Reversal, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.9a</td>
<td>Patient Education, Oral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.0b</td>
<td>Key Considerations for Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.1b</td>
<td>Adverse Effects, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.2b</td>
<td>Contraindications, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.3b</td>
<td>Precautions, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.4b</td>
<td>Pregnancy, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.5b</td>
<td>Breastfeeding, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.6b</td>
<td>Dosing, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.7b</td>
<td>Monitoring and Effect on Laboratory Testing, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.8b</td>
<td>Treatment of Bleeding/Reversal, Parenteral Antiplatelet Agents</td>
</tr>
<tr>
<td>6.9b</td>
<td>Patient Education, Parenteral Antiplatelet Agents</td>
</tr>
</tbody>
</table>

**Appendix A** Risk Factors for Thromboembolic Event

**Appendix B** Risk Factors for Bleeding during Warfarin Therapy

*Return to Table of Contents*
# Table of Contents

## Work Group Co-Leaders
Seema Maddali, MD, MHA  
Hospitalist, HealthEast Care System
Colleen Morton, MD  
Hematology/Oncology, HealthPartners Medical Group and Regions Hospital

## Work Group Members
HealthPartners Medical Group and Regions Hospital
Timinder Biring, MD  
Interventional Cardiology
Kori Krueger, MD  
Internal Medicine
Tonja Larson, PharmD, BCPS  
Pharmacy
Melissa Mikelson, RN, BSN  
Internal Medicine
Stephen Kopecky, MD  
Cardiology
Rajiv Pruthi, MBBS  
Hematology
Park Nicollet Health Services
Timothy Miley, MD  
Pathology
Anne Schullo-Feulner, PharmD, BCPS  
Pharmacy
ICSII
Jim Bluhm, MPH  
Team Director

## Algorithms and Annotations
- Index of Annotations ........................................... 1-3
- Evidence Grading ................................................. 5
- Foreword
  - Introduction .................................................. 6
  - Scope and Target Population ................................. 6
  - Clinical Highlights ........................................... 6-7
  - Related ICSI Scientific Documents ........................ 7
  - Abbreviations and Definitions .............................. 8
- Annotations ....................................................... 9-62

## Quality Improvement Support
- Implementation Tools and Resources ....................... 64
- Implementation Tools and Resources Table ................ 65-67

## Supporting Evidence
- References ....................................................... 69-79
- Appendices ....................................................... 80-81
- Appendix A – Risk Factors for Thromboembolic Event  80
- Appendix B – Risk Factors for Bleeding During Warfarin Therapy 81

## Disclosure of Potential Conflicts of Interest
- Acknowledgements ............................................... 85-86

## Document History and Development
- Document History ................................................ 87
- ICSI Document Development and Revision Process .... 88
Evidence Grading

A consistent and defined process is used for literature search and review for the development and revision of ICSI guidelines. Literature search terms for the current revision a search of clinical trials, meta-analysis, and systematic reviews restricted to human studies and English language in the following areas: fondaparinux/antagonists and inhibitors; anticoagulants Factor Xa inhibitor/antagonists and inhibitors; platelet glycoprotein GPIIb-IIIa; chromogenic factor X inhibitor; platelet aggregation/drug effects; platelet aggregation inhibitors; ticagrelor; argatroban; dabigatran; rivaroxaban, apixaban, endoxaban, otamixaban; antithrombins; pregnancy; direct thrombin inhibitors; CYP2C19; metabolizer; clopidogrel and Plavix®; ticlopidine/anlogs and derivatives. Included publications are from April 2010 to November 2011. Included are human data, English language.

Individual research reports are assigned a letter indicating the class of report based on design type: A, B, C, D, M, R, X.

Evidence citations are listed in the document utilizing this format: (Author, YYYY [report class]; Author, YYYY [report class] – in chronological order, most recent date first). A full explanation of ICSI's Evidence Grading System can be found on the ICSI Web site at http://www.icsi.org.

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary Reports of New Data Collections</strong></td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>Randomized, controlled trial</td>
</tr>
<tr>
<td>B</td>
<td>Cohort-study</td>
</tr>
</tbody>
</table>
| C | Non-randomized trial with concurrent or historical controls  
Case-control study  
Study of sensitivity and specificity of a diagnostic test  
Population-based descriptive study |
| D | Cross-sectional study  
Case series  
Case report |
| **Reports that Synthesize or Reflect upon Collections of Primary Reports** | |
| M | Meta-analysis  
Systematic review  
Decision analysis  
Cost-effectiveness analysis |
| R | Consensus statement  
Consensus report  
Narrative review |
| X | Medical opinion |

Return to Table of Contents
Foreword

Introduction

The ICSI Antithrombotic Therapy Supplement has been developed as a resource for the use of antithrombotic drugs. This is a supplemental document that brings about consistency in recommendations that are common to the scope of related ICSI guidelines. See related ICSI scientific documents: Heart Failure in Adults, Diagnosis and Initial Treatment of Ischemic Stroke, Diagnosis and Treatment of Chest Pain and Acute Coronary Syndrome (ACS), Venous Thromboembolism Diagnosis and Treatment and Venous Thromboembolism Prophylaxis.

Antithrombotic drugs are used to decrease the risk of thrombosis by interfering with the homeostatic clotting mechanism. The major side effect of these drugs is bleeding either from supratherapeutic effect or by accentuating the blood loss of patients with an existing source of bleeding.

There are few absolute contraindications to antithrombotic therapy, with the exception of active life-threatening bleeding. The decision to treat a patient with antithrombotic drugs takes into account an individual patient's risk for thrombosis if not treated weighed against the risk of bleeding while on antithrombotic drug therapy.

This supplement and related guidelines should help physicians to make that risk-benefit treatment decision. The discussions found in the supplement's annotations provide support to the clinician around difficult dosing decisions. An aim of the clinical discussion is to flesh out varied nuances of dosing decisions, which is information difficult to find when simply looking up dosing information online. This supplement is also meant to serve as a tool to use for patients treated with antithrombetics.

A glossary of abbreviations used throughout this guideline can be found on the Abbreviations and Definitions page.

Return to Table of Contents

Scope and Target Population

This guideline supplement is targeted for any adult patient receiving antithrombotic therapy. Please refer to related ICSI guidelines for specific target populations.

Return to Table of Contents

Clinical Highlights

• There are no circumstances under which patients absolutely should or should not receive anticoagulation therapy, with the exception of life-threatening bleeding. Clinicians must consider the risks and benefits of anticoagulation therapy for a patient based upon the individual's risk for thrombosis if not treated weighed against the risk of bleeding if treated. (Introduction, Annotations #1.0, 1.1, 1.2, 1.4, 1.6, 2.1, 2.2, 2.3, 2.4, 2.8, 3.2, 3.3, 3.4, 3.8, 4.0a, 4.1a, 4.1b, 4.2a, 4.2b, 4.3a, 4.3b, 4.4b, 4.8a, 4.8b, 5.0, 5.1, 5.2, 5.3, 5.4b, 5.8, 6.1b, 6.2a, 6.2b, 6.3a, 6.3b, 6.4b)

• In the initial phase of treatment for patients with active thrombosis (such as acute deep vein thrombosis [DVT]) or high risk of thrombosis, immediate-acting anticoagulant agents (UFH/LMWH/fondaparinux) should be used concomitant with warfarin. (Annotation #1.6)

• Loading doses of warfarin should be avoided. (Annotation #1.6)

Return to Table of Contents
Many prescription medications and over-the-counter remedies, including dietary supplements and herbs, may alter the effectiveness of warfarin or vitamin K antagonists (detected by the international normalized ratio) and/or reduce the effectiveness of platelets (not detected by the international normalized ratio). (Annotation #1.6)

Vitamin K may be used to reverse supratherapeutic anticoagulation with warfarin. The dose of vitamin K depends upon the degree of international normalized ratio (INR) elevation and/or signs and symptoms of bleeding. Vitamin K can lead to warfarin resistance and subsequently to an increased risk of thromboembolism. (Annotation #1.8)

Regardless of the anticoagulant used, it is important that patients know they must always inform their physician and other health care providers that they are on anticoagulation therapy, especially if they are undergoing an invasive procedure. (Annotations #1.9, 3.9, 4.9a, 5.9)

Patients should be encouraged and empowered to play an active role in the self-management of their treatment. Self-management is best initiated and sustained through active involvement of patients and family members with their multidisciplinary health care team. This educational partnership should be encouraged to decrease potential risks and improve understanding of the importance of patient adherence to his or her treatment regimen. (Annotations #1.9, 3.9, 4.9a, 4.9c, 5.9, 6.9a, 6.9b)

Recent concerns about concomitant use of proton pump inhibitors (PPI) and clopidogrel ought to be addressed on a patient-by-patient basis with discontinuation of PPI if there is no definite indication for its use; H2 blockers could be considered if acid-suppression is desired. (ICSI Antithrombotic work group consensus-based recommendation.) (Annotation #6.0a)

Dabigatran has been FDA approved for use only in non-valvular atrial fibrillation as an alternative to warfarin for stroke prevention. (Annotation #4.0)

Lepirudin was removed from the European market starting April 1, 2012, and will no longer be manufactured after May 2013. If the United States experiences absence of lepirudin, use argatroban or bivalirudin in patients with heparin-induced thrombocytopenia. (Annotation #4.0b)

Rivaroxaban has been FDA approved for the prevention of DVT and PE in patients undergoing knee or hip replacement surgery, treatment of DVT and PE and for non-valvular atrial fibrillation for stroke prevention. (Annotation #5.0)

Return to Table of Contents

Related ICSI Scientific Documents

Guidelines

- Heart Failure in Adults
- Diagnosis and Initial Treatment of Ischemic Stroke
- Diagnosis and Treatment of Chest Pain and Acute Coronary Syndrome (ACS)
- Venous Thromboembolism Diagnosis and Treatment
- Venous Thromboembolism Prophylaxis

Return to Table of Contents
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACCP</td>
<td>American College of Chest Physicians</td>
</tr>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the drug plasma concentration – time curve</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CV</td>
<td>Cardiovascular</td>
</tr>
<tr>
<td>Clinician</td>
<td>All health care professionals whose practice is based on interaction with and/or treatment of a patient</td>
</tr>
<tr>
<td>DTI</td>
<td>Direct thrombin inhibitor</td>
</tr>
<tr>
<td>DVT</td>
<td>Deep vein thrombosis</td>
</tr>
<tr>
<td>FFP</td>
<td>Fresh frozen plasma</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>HCT</td>
<td>Hematocrit</td>
</tr>
<tr>
<td>HAT</td>
<td>Heparin-associated thrombosis</td>
</tr>
<tr>
<td>HIT</td>
<td>Heparin-induced thrombocytopenia</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>INR = (patient PT/mean normal PT) (^{ISI})</td>
<td></td>
</tr>
<tr>
<td>ISI</td>
<td>International sensitivity index</td>
</tr>
<tr>
<td>LMWH</td>
<td>Low-molecular-weight heparin</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>NSAID</td>
<td>Non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>PCC</td>
<td>Prothrombin complex concentrate</td>
</tr>
<tr>
<td>PCI</td>
<td>Percutaneous coronary intervention</td>
</tr>
<tr>
<td>PE</td>
<td>Pulmonary embolism</td>
</tr>
<tr>
<td>PT</td>
<td>Prothrombin time</td>
</tr>
<tr>
<td>TIA</td>
<td>Transient ischemic attack</td>
</tr>
<tr>
<td>UFH</td>
<td>Unfractionated heparin</td>
</tr>
<tr>
<td>VTE</td>
<td>Venous thromboembolism</td>
</tr>
</tbody>
</table>

*Return to Table of Contents*
Algorithm Annotations

1. Warfarin

1.0. Introduction, Warfarin

Warfarin is used in the chronic management of patients with several types of thrombotic diseases. It produces its anticoagulant effect by inhibiting the vitamin K-dependent production of clotting factors II, VII, IX and X, as well as the anticoagulant proteins C and S. The antithrombotic effect of warfarin is dependent on reduction of factor II (prothrombin), the factor with the longest half-life of 60 to 72 hours. Because of this, warfarin is not fully effective in the initial several days of therapy (Ansell, 2008 [R]).

When determining the efficacy and tolerability of warfarin in patients with non-valvular atrial fibrillation, the clinical trials excluded patients using the following criteria:

Table 1: Exclusion Criteria Used in Trials Evaluating the Efficacy and Tolerability of Anticoagulation in Patients with Non-Valvular Atrial Fibrillation

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Active bleeding</td>
</tr>
<tr>
<td>Active peptic ulcer disease</td>
</tr>
<tr>
<td>Known coagulation defects</td>
</tr>
<tr>
<td>Thrombocytopenia (platelets less than 50,000/mm³) or platelet dysfunction</td>
</tr>
<tr>
<td>Recent hemorrhagic stroke</td>
</tr>
<tr>
<td>Non-compliant or unreliable patients</td>
</tr>
<tr>
<td>Patient is psychologically or socially unsuitable</td>
</tr>
<tr>
<td>Dementia or severe cognitive impairment</td>
</tr>
<tr>
<td>History of falls (three within the previous year or recurrent, injurious falls)</td>
</tr>
<tr>
<td>Excessive alcohol intake</td>
</tr>
<tr>
<td>Uncontrolled hypertension (greater than 180/100 mm Hg)</td>
</tr>
<tr>
<td>Daily use of non-steroidal anti-inflammatory drugs (NSAIDs)</td>
</tr>
<tr>
<td>Planned invasive procedure or major surgery</td>
</tr>
</tbody>
</table>

(Sebastian, 2000 [R])

Used with permission from Drugs and Aging 2000, Jun:16(6) 409-435.

The clinician will need to balance the potential increased risk in bleeding against the potential decreased risk of thromboembolism when evaluating warfarin therapy.

1.1. Adverse Effects, Warfarin

Key Points:

- The most common adverse effect of warfarin is bleeding. Risk factors for bleeding include patient-related and treatment-related factors.
Bleeding

Patients treated with usual doses of warfarin have a 2-4% risk per year of bleeding episodes requiring transfusion, and a 0.2% risk per year of fatal hemorrhage. Risk factors for bleeding include patient-related factors and treatment-related factors.

**Patient-related factors** include age, previous episodes of bleeding, anemia (hematocrit less than 30%), hypertension, heart disease, cerebrovascular disease, renal disease, history of gastrointestinal hemorrhage, active peptic ulcer disease or liver disease, recent or imminent surgery, trauma, excessive alcohol intake, unreliability, frequent or significant falls, regular use of non-steroidal anti-inflammatory (NSAIDs), and use of other medications or natural remedies. In 1998, Beyth, Quinn and Landefeld published a prediction rule for estimation of the risk of bleeding while on outpatient warfarin therapy. The prediction rule was derived from a cohort of 565 patients who started outpatient warfarin upon discharge from Brigham and Women's Hospital between 1977 and 1983. The cohort was followed from 1983 to 1985. The prediction rule was then tested prospectively on a cohort of 264 consecutive patients who started outpatient warfarin therapy upon discharge from University Hospitals of Cleveland between April 1986 and April 1987. Patients were followed through June 1993 or until cessation of anticoagulation therapy, or death (Beyth, 1998 [B]). It is worth noting that both cohorts were derived from patients who were deemed appropriate for outpatient warfarin therapy by their primary physicians. There was no description of the patients who were not enrolled in the trial. Trials evaluating the safety and effectiveness of oral anticoagulants in patients with atrial fibrillation excluded 80% of patients on the basis of factors presumed to increase their risk of bleeding (Levine, 2004 [R]; Sebastian, 2000 [R]; Landefeld, 1993 [R]). Few, if any, patients with the above noted risk factors have been formally studied.

The Food and Drug Administration (FDA) recently approved updated labeling for warfarin. The agency reports that people with variations in two genes, CYP2C9 and VKORC1, are individually responsible for 35-50% of the variable dose response to warfarin (Wood, 2007 [R]). These genetic variations affect the dose of warfarin that individual patients will need to achieve and maintain therapeutic INRs. This issue is discussed further under initiation of warfarin in Annotation #1.6, "Dosing, Warfarin."

Advanced patient age and hypertension are two predictors of risk strongly related to the inherent risk of intracerebral hemorrhage in patients not receiving anticoagulation (Hart, 1995 [R]). Combined literature sources support age as a risk for intracerebral hemorrhage that increases by 1.85/year/decade, with particular caution above 75 years of age (Hart, 2005 [R]; Hart, 1998 [M]; Hart, 1995 [R]). Retrospective analysis of over 10,000 patients over the age of 65 (mean age 77) identified a threefold increased risk (RR 3.0, 95% CI 1.6-6.5) of intracerebral hemorrhage in patients receiving both antiplatelet and warfarin therapy (Hart, 2005 [R]).

**Treatment-related factors** include duration, intensity and variability of warfarin treatment, concomitant use of aspirin, and support patients receive from their providers and home environments. Please refer to Appendix A, "Risk Factors for Thromboembolic Event," and Appendix B, "Risk Factors for Bleeding during Warfarin Therapy." For additional information on bleeding risk in anticoagulation therapy, see http://circ.ahajournals.org/content/110/16/2287.

Risk factors for bleeding should not be considered absolute contraindications to anticoagulant therapy. Some risk factors for bleeding (such as age) are also risk factors for thromboembolism. The potential increased risk of bleeding must be balanced against the potential decreased risk of thromboembolism. (Levine, 2004 [R]; Palareti, 2000 [C]; Sebastian, 2000 [R]; Fihn, 1996 [B]; Hylek, 1994 [C]; Fihn, 1993 [B]; Landefeld, 1993 [R]; Launbjerg, 1991 [D]; Landefeld, 1989a [B]; Landefeld, 1989b [C])
Skin Necrosis

Skin necrosis is a rare but serious complication of warfarin therapy that can occur in two situations 1) in patients with acute heparin-induced thrombocytopenia (HIT) and 2) in patients with pre-existing congenital protein C or protein S deficiency.

1) HIT-associated skin necrosis: Generally occurs in patients who have active HIT when warfarin is prematurely initiated or initiated in high/loading doses.

2) Skin necrosis associated with congenital protein C/S deficiency (incidence 0.01-0.1%): Patients initiated on warfarin without heparin bridging may develop skin necrosis that typically occurs on the third to eighth day of therapy.

Patients present with painful localized skin lesions due to thrombosis of venules and capillaries within subcutaneous fat. These lesions may occur in areas of fatty tissue such as the breasts, abdomen or even in extremities. Warfarin should be discontinued in patients with suspected skin necrosis. Direct thrombin inhibitor (DTI), should be initiated or continued in patients with HIT. Warfarin has been successfully used in such cases by initiating very low doses while continuing heparin/DTI and gradually escalating the dose over several weeks to avoid an abrupt drop in protein C levels before coagulation factors levels are reduced (Jillela, 1996 [D]). Because of the extreme rarity of this complication, routine pretesting for congenital protein C and protein S deficiency in all individuals prior to initiation of oral anticoagulation is not advised (Beitz, 2002 [R]; Chan, 2000 [R]; Makris, 1996 [D]). However, if there is a strong family history of venous thromboembolism, such testing should be considered.

Purple Toe Syndrome

Purple toe syndrome and other manifestations of peripheral emboli may rarely complicate warfarin therapy, usually 3-10 weeks after initiation of therapy. Causes of purple toe syndrome other than warfarin should be considered when making a treatment decision. These include vasculitis, acute myocardial infarction (MI) with embolism, and diabetes mellitus.

(Lamm, 2003 [D]; Sallah, 1997 [R]; Abdelmalek, 1995 [D]; Assel, 1993 [R]; Hyman, 1987 [D])

Less Serious Adverse Effects

Adverse effects that are less serious include alopecia, osteoporosis, gastrointestinal discomfort and rash. Management of these adverse effects should be managed on an individual basis.

(Caraballo, 1999 [B]; Jamal, 1998 [B]; Umlas, 1988 [D]; Kwong, 1978 [D]; Cornbleet, 1957 [D])

1.2. Contraindications, Warfarin

Key Points:

- All contraindications are relative to a patient's risk for thrombosis weighed against the risk for bleeding while on anticoagulation therapy.

Warfarin Allergy or Intolerance

Acute rash, hepatitis, diarrhea or nausea may indicate an allergy or intolerance to warfarin.

Hemorrhage

Anticoagulation with warfarin is contraindicated in patients with active hemorrhage. The decision to initiate anticoagulation should be individualized for patients with a history of recent hemorrhage. Again, this is dependent on circumstances including the type of hemorrhage and the indication for anticoagulation. Withholding anticoagulation for four to six weeks may be prudent for non-central nervous system
bleeds. This duration may be longer for central nervous system (CNS) bleeds and needs to be assessed on a case-by-case basis.

Please refer to Annotation #1.1, "Adverse Effects, Warfarin," for additional information about predicting the risk of bleeding for individual patients.

**Pregnancy**

See Annotation #1.4, "Pregnancy, Warfarin – High Risk."

### 1.3. Precautions, Warfarin

**Combined Warfarin and Antiplatelet Therapy**

In general, it is not recommended that antiplatelet medications (e.g., aspirin, clopidogrel) be added to warfarin therapy unless there is a strong need for both therapies. Combined use of these agents has been shown to increase bleed risk two- to threefold. Patients with risk factors for atherosclerotic cardiovascular disease (e.g., diabetes, hypertension) and those with chronic stable atherosclerotic cardiovascular disease can usually be started on warfarin with the discontinuation of the antiplatelet therapy.

Circumstances that may necessitate the combined use of antiplatelet drugs and warfarin may include patients with mechanical valves, patients with acute coronary syndrome or patients with recent coronary stents or bypass surgery. This is categorized as a 2C, weak recommendation, by the American College of Chest Physicians (*American College of Chest Physicians, 2012 [R]*). However, even in these circumstances, the patient’s individual bleeding risk should be taken into account. If bleed risk is prohibitive with combined use, one could consider discontinuing warfarin or decreasing the target INR in order to lower that patient’s risks.

Consultation with an anticoagulation expert may be helpful in determining the risks and benefits of combined warfarin and antiplatelet use.

(*Madhwal, 2008 [R]; Dentali, 2007 [M]; Hart, 2005 [R]*)

### 1.4. Pregnancy, Warfarin – High Risk

Recommendations regarding the use of warfarin during pregnancy are difficult due to lack of prospective data. Clinical guidelines are based mainly on retrospective data.

The manufacturer of warfarin states that it is contraindicated during pregnancy secondary to embryopathy associated with use during the first trimester, weeks 6-12 and CNS abnormalities from exposure during any trimester. The risk of embryopathy appears to be between 4 and 10%. The risk may be lower if the dose of warfarin is less than 5 mg per day.

If the mother is taking warfarin at the time of delivery, the rate of fetal intracranial hemorrhages during delivery is increased. If patients remain on warfarin during pregnancy, warfarin should be discontinued and continuous intravenous unfractionated heparin should be started 2-3 weeks prior to delivery (*Bates, 2004 [R]*)

In patients with mechanical heart valves, the decision of whether to continue warfarin or use unfractioned heparin or low-molecular-weight heparin during the first trimester and throughout pregnancy should be made after a discussion with an anticoagulation expert with regards to the risk and benefits (*Nishimura, 2008 [R]*)

For further recommendations, please see the ACC/AHA 2008 Guideline Update on Valvular Heart Disease: Focused Update on Infective Endocarditis.
1.5. Breastfeeding, Warfarin

The amount of warfarin in breast milk is too small to affect the baby. As a result, breastfeeding is safe for mothers taking warfarin and for their infants.

1.6. Dosing, Warfarin

Key Points:

- Patients receiving warfarin for the first time should begin at the patient's estimated average daily dose (typically 5 mg/day; range 2.5-7.5 mg/day), with a recheck of the INR in two to three doses.
- Steady-state INR values will not be realized for up to three weeks following a dose adjustment.

*(Nichols-English, 2000 [R]*)

**Testing should be obtained before initiation of warfarin:**

- Complete blood count (CBC)
- Platelet count
- INR
- aPTT
- Creatinine
- Liver enzymes (ALT, AST, GGT)
- Albumin

**General Principles of Warfarin Dosing**

Except in certain circumstances as noted, loading doses of warfarin should not be used. Warfarin (irrespective of INR) is not fully effective in the first several days of therapy because of a delayed decrease in several circulating clotting factors. Loading doses can increase a patient's risk of supratherapeutic INR and make it more difficult to determine a steady-state dose *(Crowther, 1999 [A]; Beyth, 1998 [B]).*

Studies have compared patients initiated on 10 mg versus 5 mg of warfarin. Although the 10 mg group achieved a therapeutic INR sooner (44% at 36 hours versus 8% at 36 hours), there was also a greater incidence of supratherapeutic anticoagulation in patients given the higher initial dose. A follow-up study of similar design showed equal efficacy in achieving a therapeutic INR for patients given 5 mg versus 10 mg initial warfarin dosing *(Ansell, 2008 [R]; Kovacs, 2003 [A]; Hylek, 2001 [B]; Harrison, 1997 [A]).* Comparison between 10 mg and 5 mg loading doses of warfarin does not result in a quicker therapeutic INR at day 4 or 5 with the higher dose *(Crowther, 1999 [A]).* Comparison between 10 mg and 5 mg loading doses demonstrates less excess anticoagulation with the 5 mg dose. Further, the 5 mg dose avoids a potential hypercoagulable state caused by decline in Protein C, an endogenous anticoagulant *(Harrison, 1997 [A]).*

For patients sufficiently healthy being treated as outpatients, the ACCP 2012 guidelines suggest initiating warfarin at 10 mg once daily for the first two days followed by dosing based on INRs rather than starting with the estimated maintenance dose. This is categorized as a 2C, weak recommendation, by the American College of Chest Physicians *(Guyatt, 2012 [R]).*
The FDA approved updated labeling for warfarin. The agency reports that people with variations in two genes, CYP2C9 and VKORC1, are individually responsible for 35-50% of the variable dose response to warfarin (Wood, 2007 [R]). These genetic variations affect the dose of warfarin that individual patients will need to achieve and maintain therapeutic INRs. This issue is discussed further under initiation of warfarin in this annotation.

Patients at high risk for thrombosis, such as those with an active thrombotic process (e.g., VTE) or an underlying malignancy, should be initially treated with concomitant immediate-acting anticoagulant (UFH, LMWH, fondaparinux, DTIs) and warfarin therapy. Patients at lower thrombotic risk (e.g., atrial fibrillation without recurrent thromboembolism) can be initiated on warfarin alone.

Most of the indications for warfarin therapy require a recommended target INR of 2.5, with a therapeutic INR range of 2.0 to 3.0. Examples of clinical indications with this target INR and recommended range include venous thrombosis and pulmonary embolism, chronic atrial fibrillation, mitral bioprosthetic valves and some cases of rheumatic valvular heart disease. Other clinical situations are at higher risk for thromboembolic events and require a target INR of 3.0 with a therapeutic INR range of 2.5 to 3.5. Examples of these clinical indications include mitral mechanical valves and rheumatic mitral valve disease associated with left atrial thrombus.

Please refer to the antithrombotic therapy for atrial fibrillation and valvular disease sections of the American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis, 9th edition for target INR recommendations in specific cardiac situations.

The risk of bleeding for patients on warfarin increases substantially at INR values greater than 4.0. This risk is magnified if one or more risk factors are present. Consider hemorrhagic risk in all dosing decisions. Please refer to Appendix B, "Risk Factors for Bleeding during Warfarin Therapy."

There is a significant increase in thromboembolism as INR values decrease below INR 1.7. Clinical risk and past medical history should be considered in all dosing decisions. Higher risk may require more aggressive dosing.

In most cases, holding warfarin for four days prior to surgery results in an INR value of 1.2 or less. Expect advanced age and drug interactions to result in a slower decline. Patients with high risk of thromboembolism may need coverage with heparin for a portion of this time.

Some equivalency studies have shown that substitution of generic warfarin for brand name Coumadin® may provide equivalent anticoagulation response if the manufacturer of the generic warfarin has followed the standards set for the name brand (Weibert, 2000 [A]; Yacobi, 2000 [A]). Care must be taken to remain with either the brand name product or the same generic product. Do not switch from brand to generic or between generics. If a switch must be made, monitor the INR more frequently.

Prescription and over-the-counter medications can adversely affect the INR response to warfarin. Dietary supplements including herbal or natural remedies can change the INR response to warfarin and/or increase a patient's risk of bleeding. In these instances, additional monitoring may be needed.

Mechanisms of drug-drug interactions occur commonly by the cytochrome P450 enzyme metabolizing system. Metabolism of the object or substrate medication may either be induced or inhibited by the interacting drug. Induction will result in a diminished pharmacodynamic response, while inhibition will result in an increased pharmacodynamic response.

Foods that contain moderate amounts of vitamin K may decrease the INR response to warfarin. Patients should be encouraged to not change their diet while taking warfarin and not change the amount of foods containing vitamin K they normally eat each day. Please refer to Annotation #1.9, "Patient Education, Warfarin," for a guide to educating patients regarding warfarin therapy.

Direct thrombin inhibitors and heparins can affect the INR. Please refer to Annotations #4.0-4.9b, "Direct Thrombin Inhibitors (DTI)," for more information.
Initiation of Warfarin

The benefits and risks of the addition of aspirin, heparin and/or a low-molecular-weight heparin to warfarin during initiation vary from disease to disease. Please see the disease-specific ICSI guidelines on the Web site:

- Diagnosis and Initial Treatment of Ischemic Stroke
- Diagnosis and Treatment of Chest Pain and Acute Coronary Syndrome (ACS)
- Venous Thromboembolism Diagnosis and Treatment
- Venous Thromboembolism Prophylaxis

Average daily dosing technique (for patients not on heparin)

Average daily dosing technique is useful for patients off UFH and LMWH.

A baseline INR value should be drawn to rule out underlying coagulopathy.

Patients previously taking warfarin can be initiated at the previous dose.

Patients receiving warfarin for the first time should begin at an average dose of 5 mg daily, with a recheck of INR in two to three doses. Lower initiation doses should be considered for patients with any of the following factors: age greater than 75 years, multiple comorbid conditions, poor nutrition (low albumin), elevated INR when off warfarin, elevated liver function tests, or changing thyroid status. For patients who weigh more than 80 kg, a higher estimated average initial dose of 7.5 mg may be given. Higher initial dosing nomograms have not shown consistent benefit. Loading doses can increase a patient's risk of supratherapeutic INR and make it more difficult to determine a steady-state dose (Crowther, 1999 [A]; Beyth, 1998 [B]).

If the INR is 2.0 or greater after the first three doses, consider decreasing the dose by one-half. Always search for causes of rapid rise in INR such as drug interactions, poor nutritional status, infection or systemic disease process.

Subsequent INR values are determined at two to three times weekly for one to two weeks, then less often depending on the stability of the INR result.

Steady-state anticoagulation occurs between 6 to 12 days. Expect obese patients and patients of advanced age to take longer to reach steady state.

(Fennerty, 1984 [D]; O'Connell, 2000 [D]; Blann, 1999 [D])

Flexible daily dosing technique (for inpatients and outpatients on heparin)

The flexible daily dosing technique is useful for patients on concomitant UFH or a LMWH.

A baseline INR value may be drawn to rule out underlying coagulopathy.

Patients are given daily doses of warfarin, adjusted according to the daily INR, until a weekly dose can be determined (Fennerty, 1984 [D]).

The dose-response relationship is best interpreted when there are at least 16 hours between dose and laboratory draw.

Use of genomic and clinical prediction rules

The FDA approved updated labeling for warfarin. The agency reports that people with variations in two genes, CYP2C9 and VKORC1, are individually responsible for 35-50% of the variable dose response to warfarin (Wood, 2007 [R]). These genetic variations affect the dose of warfarin that individual patients will need to achieve and maintain therapeutic INRs.
Several studies have demonstrated that these genetic variations do have some influence on the warfarin dose a patient may require (Caraco, 2007 [A]). A recent trial used a prediction rule combining genomic testing data with clinical characteristics in predicting a patient's dosing needs. This rule appeared to better predict the eventual weekly dosing needs of patients who required higher or lower doses of warfarin compared to standard dosing techniques such as flexible dosing nomograms or a clinical algorithm. This study does not address the issue of whether a precise initial dose of warfarin translates into improved clinical endpoints, such as a reduction in the time needed to achieve a stable therapeutic INR, fewer INRs that are out of range, and a reduced incidence of bleeding or thromboembolic events. However, this study lays important groundwork for a prospective trial and suggests that such a trial should be powered to detect the benefits of incorporating pharmacogenetic information into the dose algorithm for patients who require high or low doses (The International Warfarin Pharmacogenetics Consortium, 2009 [B]).

The CHEST guidelines recommend against routine use of pharmacogenetic testing for patients initiating on warfarin. This is categorized as a 1B, strong recommendation, by the American College of Chest Physicians (American College of Chest Physicians, 2012 [R]). The work group feels that more clinical trials are necessary before recommending routine testing of patients for these genetic variations. There are many other variables that influence a patient's response to warfarin therapy. Most important is that all patients initiating warfarin need frequent, careful monitoring to assess their response to this therapy.

### Maintenance Dosing of Warfarin

An assessment of clinical variables known to affect the INR (including a change of patient adherence, change of other medications [e.g., amiodarone], change of food or alcohol consumption, change of activity level) should be made with each dose adjustment. Always search for the cause of out-of-range values and address them before adjusting the dose.

Expect a 15% dose adjustment to result in an approximately 1.0 INR change. Likewise, a 10% dose adjustment will result in an approximate 0.7-0.8 INR change.

Steady-state INR values will not be realized for up to three weeks following a dose adjustment.

The ACCP guideline recommends that patients with a single out-of-range INR value less than 0.5 above or below therapeutic range be maintained on the current dose and repeat the INR within one to two weeks. Use of low-molecular-weight heparins or heparin in this situation is not recommended (American College of Chest Physicians, 2012 [R]). This is categorized as a 2C, weak recommendation, by the American College of Chest Physicians (American College of Chest Physicians, 2012 [R]).

If two consecutive weekly INR values are within range and there has not been a change in clinical variables known to effect the INR, the interval between draws may be gradually increased to monthly, and not more than six weeks. For patients with consistently stable INRs, the ACCP guideline recommends an INR frequency up to 12 weeks rather than every four weeks. This is categorized as a 2C, weak recommendation, by the American College of Chest Physicians (American College of Chest Physicians, 2012 [R]).

### Options for dosing management

Anticoagulation clinics have been shown to significantly reduce patients' risks of adverse events.

Though traditionally warfarin has been monitored at a central laboratory and managed by the patient's physician, new monitoring and management options have emerged.

Anticoagulation clinics staffed by pharmacists and registered nurses have been shown to significantly reduce patients' risks of adverse events. There are published "before and after" design trials comparing patients whose warfarin was managed by their personal physicians with patients whose warfarin was managed by anticoagulation clinics (Chiquette, 1998 [C]; Wilt, 1995 [D]; Cortelazzo, 1993 [D]; Garabedian-Ruffalo, 1985 [D]). All five trials reported reductions in the incidence of major hemorrhage and thromboembolism.
Beyth et al. published a randomized control trial of 325 patients 65 years of age and older that compared patients whose warfarin was managed by their personal physicians with patients whose warfarin was managed by anticoagulation clinics (Beyth, 2000 [B]; Chiquette, 1998 [C]; Wilt, 1995 [D]; Cortelazzo, 1993 [D]; Garabedian-Ruffalo, 1985 [D]). See the Implementation Tools and Resources Table for more resources for the development and support of anticoagulation clinics.

Computer-assisted dosing has been slow to develop but may someday improve the quality of anticoagulation adjustments and offer superior management for difficult or high-risk patients (Beyth, 2005 [R]; Menendez-Jandula, 2005 [A]).

**Patient Self-Testing and Self-Management**

- **Patient self-testing** is when a patient performs an INR at home and receives dosing instructions from a medical provider (e.g., physician or anticoagulation clinic).

- **Patient self-management** is when a patient performs an INR at home and uses an algorithm to guide dosing, without necessarily interacting with a medical provider (Ansell, 2005 [R]). Patient self-management is not presently approved by Medicare.

Although patient self-testing of the INR in warfarin therapy has been practiced successfully in Europe for many years, this approach has not been widely adopted in the United States. In 2008, the Centers for Medicare and Medicaid Services (CMS) expanded the covered indications for patient self-testing of the INR to include the common conditions of atrial fibrillation and venous thromboembolism (CMS, 2008 [NA]). Despite this change, only 1% of warfarin patients in the United States participate in a self-testing program (Finkel, 2010 [X]).

Previous studies have suggested that patient self-testing resulted in superior outcomes related to stroke, major bleeding and death (Heneghan, 2006 [M]). However, a recent large randomized clinical trial showed equivalent outcomes when weekly patient self-testing was compared to monthly, high-quality testing in an anticoagulation clinic. The patient self-testing group did show significant improvement of the secondary outcomes of time within the therapeutic range, patient satisfaction with anticoagulation therapy and quality of life (Matchar, 2010 [A]).

A consensus guideline has been published detailing a recommended approach to developing a patient self-testing and/or self-management program (Ansell, 2005 [R]). Critical elements of a self-testing program include appropriate patient (or caregiver) selection for adequate cognition, vision and dexterity, a structured, face-to-face patient education program carried out by a trained staff, formal patient testing to confirm understanding of required information, weekly patient testing and ongoing supervision by a physician or training center. Coagulometers selected for self-testing should give similar results to the laboratory INR testing. These meters should be compared to the laboratory INR or a central point-of-care laboratory instrument at least annually.

If self-management programs are approved by Medicare in the future, they would require ongoing support from a physician or anticoagulation clinic for a variety of issues including situations where maintaining appropriate anticoagulation were difficult, planned surgical intervention requiring bridging and ongoing education (Ansell, 2005 [R]).

**Warfarin Perioprocuderal Management**

**Anticoagulation Bridging**

Interuption of chronic warfarin therapy is occasionally needed when patients undergo procedures. To achieve adequate hemostasis, warfarin is held for 4-5 doses (depending on patient's INR range) prior to procedure. Warfarin is then restarted within 12-24 hours following the procedure but does not achieve an adequate anticoagulation effect for at least five days. Therefore, patients who hold warfarin therapy for procedures...
have a 7-10 day period when they are not receiving antithrombotic protection from warfarin. Depending on the patient's circumstances, a decision is sometimes made to "bridge" this interval off warfarin with a shorter-acting parenteral anticoagulant such as IV UFH or LMWH. However, bridge therapy can increase the patient's risk of procedure-related bleeding, especially when given immediately after the procedure. The decision to use short-acting parenteral anticoagulants or simply hold warfarin without bridging takes into account the individual patient's risk of a thrombotic event off warfarin weighed against his/her risk of bleeding complications from the procedure and parenteral anticoagulants. The table below gives examples of cardiac conditions with variable risks of thromboembolic events.

Table 2. Risk of Thrombotic Complications in the Absence of Anticoagulation Therapy

<table>
<thead>
<tr>
<th>Condition</th>
<th>% Thrombotic Risk*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrial fibrillation (low risk)</td>
<td>1</td>
</tr>
<tr>
<td>Atrial fibrillation (average risk)</td>
<td>5</td>
</tr>
<tr>
<td>Atrial fibrillation (high risk)</td>
<td>12</td>
</tr>
<tr>
<td>Aortic valve prosthesis (bi-leaflet – St. Jude/Medtronic Hall)</td>
<td>4-10</td>
</tr>
<tr>
<td>Aortic valve prosthesis (single-leaflet – Bjork-Shiley)</td>
<td>23</td>
</tr>
<tr>
<td>Mitral valve prosthesis (dual-leaflet – St. Jude)</td>
<td>22</td>
</tr>
<tr>
<td>Multiple prosthesis (St. Jude)</td>
<td>91</td>
</tr>
</tbody>
</table>

*Annualized
(Ansell, 2008 [R]; Douketis, 2008 [R])

Low Bleeding Risk Procedures

For most dental procedures, a review of the literature has shown that in most cases no change in warfarin is needed (Ansell, 2008 [R]). It may be reasonable to allow the patient to "drift" to the low end of his/her therapeutic INR prior to a dental procedure with a higher risk of bleeding. Warfarin can be held two to three days prior to dental procedure to achieve this goal.

Local bleeding may be controlled with a variety of techniques including pressure, biting on tea bags, gelatin sponges and topical thrombin. Other means of local hemostasis control include tranexamic acid mouthwash or epsilon aminocaproic acid packing (Wahl, 1998 [R]; White, 1995 [D]).

Other examples of procedures with low bleeding risk include skin biopsies, ureteral stent placement, paracentesis, and cataract surgery. Patients who have procedures that are of low bleeding risk can be continued on warfarin anticoagulation without interruption.

For gynecologic and orthopedic surgical patients at low risk for bleeding, the warfarin dose may be lowered four to five days before surgery and the surgery performed at a lower INR (INR 1.3-1.5). The warfarin dose can be increased to the previous dose postoperatively (Ansell, 2008 [R]). Table 4 lists low-risk bleed procedures (Ansell, 2008 [R]).
Table 3. Low Bleeding Risk Procedures That Can Be Performed without Discontinuing Warfarin

<table>
<thead>
<tr>
<th>Dental</th>
<th>Dermatologic</th>
<th>Gastrointestinal/Genitourinary</th>
<th>Ophthalmic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endodontics</td>
<td>Mohs’ surgery</td>
<td>Biliary stent without sphincterotomy</td>
<td>Cataract surgery</td>
</tr>
<tr>
<td>Periodontal therapy</td>
<td>Simple excisions</td>
<td>Colonoscopy without biopsy</td>
<td>Trabeceuctomy</td>
</tr>
<tr>
<td>Prosthetics</td>
<td>Skin biopsy</td>
<td>Diagnostic endoscopic retrograde cholangiopancreatography</td>
<td></td>
</tr>
<tr>
<td>Restorations</td>
<td></td>
<td>Diagnostic esophagastroduodenoscopy</td>
<td></td>
</tr>
<tr>
<td>Teeth cleaning</td>
<td></td>
<td>Endoscopic ultrasonography without biopsy</td>
<td></td>
</tr>
<tr>
<td>Uncomplicated extractions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paracentesis and ureteral stent placement</td>
<td>Paracentesis and ureteral stent placement</td>
<td>Paracentesis and ureteral stent placement</td>
<td></td>
</tr>
</tbody>
</table>

Procedures considered to have a high bleeding risk include cardiac surgery, neurosurgery, abdominal surgery, spinal anesthesia and surgeries involving major organs. Additional determinants of bleeding risk include advanced age, comorbidities and concomitant use of antiplatelet therapy.

**Thrombotic Risk Stratification**

The ACCP has generated a grid, shown in Table 4, to help define the relative risk of thromboembolism in patients with different criteria for anticoagulation. This may be used as a guide for decision-making when determining when patients might warrant bridging with parenteral anticoagulation versus holding warfarin therapy.

Table 4. ACCP’s Suggested Risk Stratification for Perioperative Thromboembolism *

<table>
<thead>
<tr>
<th>Risk Stratification</th>
<th>Mechanical Heart Valve</th>
<th>Atrial Fibrillation</th>
<th>VTE</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>• Any mitral valve prosthesis</td>
<td>• CHADS$_2$ score of 0 to 2</td>
<td>• Recent (within 3 mo) VTE</td>
</tr>
<tr>
<td></td>
<td>• Atrial septal defect</td>
<td>• Recent (within 3 mo) stroke or transient ischemic attack</td>
<td>• Severe thrombophilia (eg, deficiency of protein C, protein S, or antithrombin; antiphospholipid antibodies; multiple abnormalities)</td>
</tr>
<tr>
<td></td>
<td>• Recent (within 6 mo) stroke or transient ischemic attack</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Moderate</td>
<td>• Biodegradable aortic valve prosthesis and one or more of the</td>
<td>• CHADS$_2$ score of 0 to 2</td>
<td>• VTE within the past 1-12 mo</td>
</tr>
<tr>
<td></td>
<td>following risk factors: atrial fibrillation, prior stroke</td>
<td></td>
<td>• Nonsevere thrombophilia (eg, heterozygous factor V Leiden or prothrombin gene mutation)</td>
</tr>
<tr>
<td></td>
<td>or transient ischemic attack, hypertension, diabetes, congestive heart failure, age &gt; 75 y</td>
<td></td>
<td>• Recurrent VTE</td>
</tr>
<tr>
<td></td>
<td>• CHADS$_2$ score of 0 to 2 (assuming no prior stroke or transient ischemic attack)</td>
<td></td>
<td>• Active cancer (treated within 6 mo or palliative)</td>
</tr>
<tr>
<td>Low</td>
<td>• Biodegradable aortic valve prosthesis without atrial fibrillation and no other risk factors for stroke</td>
<td>• VTE &gt; 12 mo previous and no other risk factors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• CHADS$_2$ score of 0 to 2 (assuming no prior stroke or transient ischemic attack)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CHADS$_2$ = congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, and stroke or transient ischemic attack; VKA = vitamin K antagonist.

*High-risk patients may also include those with a prior stroke or transient ischemic attack occurring ≥ 3 mo before the planned surgery and a CHADS$_2$ score ≤ 5, those with prior thromboembolism during temporary interruption of VKAs, or those undergoing certain types of surgery associated with an increased risk for stroke or other thromboembolism (eg, cardiac valve replacement, carotid endarterectomy, major vascular surgery).


The CHADS$_2$ score ranges from 0 to 6 and is based on whether any of five risk factors are present. There is one point for each risk factor: congestive heart failure, hypertension and diabetes, age ≥ 75 years, and two points for prior stroke or transient ischemic attack (*Douketis, 2008 [R]).

*Return to Annotation Table*  *Return to Table of Contents*
Options for Anticoagulation Management Around the Time of Procedures

A summary of options for patients on anticoagulation to consider at the time of procedure is listed in Table 5. Clinicians should use their judgment and patient preferences in determining a final course of action.

Table 5. Perioperative Anticoagulation Management

<table>
<thead>
<tr>
<th>Patient Bleeding Risk for Procedure</th>
<th>Low</th>
<th>High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>Continue warfarin</td>
<td>Hold warfarin 5 days (4 doses) prior to procedure Restart day of procedure</td>
</tr>
<tr>
<td>Moderate</td>
<td>Continue warfarin</td>
<td>Hold warfarin 5 days (4 doses) prior to procedure Consider parenteral anticoagulant bridge (LMWH or UFH) - If cardio embolic risk, use therapeutic dosing - If VTE risk, use prophylactic dosing</td>
</tr>
<tr>
<td>High</td>
<td>Continue warfarin</td>
<td>Parenteral anticoagulant bridging (LMWH or UFH), therapeutic dosing</td>
</tr>
</tbody>
</table>

(Jaffer, 2009 [R]; Douketis, 2008 [R])

Timing of Anticoagulation Management for Procedures

An example of a bridge protocol for patients receiving therapeutic parenteral anticoagulation therapy is shown in Table 6. Please be aware that studies have shown a significant risk for bleeding associated with therapeutic parenteral anticoagulation bridging. Patients should be made aware of both the thrombotic and bleeding risks associated with this approach and be involved in the final decision on bridging. There are no FDA-approved schedules for bridging.

Return to Annotation Table  Return to Table of Contents
Table 6: Recommended Bridging Schedule

<table>
<thead>
<tr>
<th>Days before Procedure</th>
<th>Warfarin</th>
<th>INR</th>
<th>Full-Dose (Therapeutic)* LMWH** or Therapeutic UFH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Five days prior to procedure</td>
<td>Last dose</td>
<td>Check if not done within two weeks prior</td>
<td>4-5 doses before procedure, start after first missed warfarin dose if at very high risk of thrombosis.</td>
</tr>
<tr>
<td>Four days prior to procedure</td>
<td>None</td>
<td>None</td>
<td>4-5 doses before procedure, start after first missed warfarin dose if at very high risk of thrombosis.</td>
</tr>
<tr>
<td>Three days prior to procedure</td>
<td>None</td>
<td>None</td>
<td>a.m. and p.m. dose**</td>
</tr>
<tr>
<td>Two days prior to procedure</td>
<td>None</td>
<td>None</td>
<td>a.m. and p.m. dose**</td>
</tr>
<tr>
<td>One day prior to procedure</td>
<td>None</td>
<td>Check INR. If INR greater than 1.5, consider 1-2.5 mg vitamin K by mouth.</td>
<td>LMWH – last dose 24 hours prior to surgery UFH IV – last dose 4-6 hours prior to surgery UFH SubQ – last dose 4 hours prior to surgery</td>
</tr>
<tr>
<td>Procedure</td>
<td>Resume at regular dose that evening</td>
<td>None</td>
<td>Start at least 12 hours post-procedure. If the patient needs therapeutic-dose LMWH; if the bleeding risk is low, resume therapy 24 hours after surgery. If the bleeding risk is high, delay starting therapeutic-dose LMWH until 48-72 hours after surgery.</td>
</tr>
<tr>
<td>One day after procedure</td>
<td>Regular dose</td>
<td>As indicated – may be skipped</td>
<td>Restart if hemostasis achieved</td>
</tr>
<tr>
<td>Two days after procedure</td>
<td>Regular dose</td>
<td>As indicated</td>
<td>Restart if hemostasis achieved</td>
</tr>
<tr>
<td>Three days after procedure</td>
<td>Regular dose</td>
<td>As indicated</td>
<td>Continue until INR greater than minimum acceptable x 2/day</td>
</tr>
<tr>
<td>Four days after procedure</td>
<td>Regular dose</td>
<td>Daily until INR greater than 2.0 then as indicated</td>
<td>Discontinue</td>
</tr>
</tbody>
</table>

* Therapeutic refers to full-dose UFH and LMWH for venous thrombosis and not cardio embolic prevention.

** If enoxaparin is used as the LMWH, dosing is every 12 hours (a.m. and p.m.). Once-a-day dosing is used if the LMWH is tinzaparin or dalteparin.

Note: Because of long half-life, fondaparinux is not recommended for bridging.

Used with permission from Park Nicollet Health Services.
Neuraxial Blockade Management (Spinal/Epidural)

Please see the ICSI Venous Thromboembolism Prophylaxis guideline.

1.7. Monitoring, Warfarin Test

The International Normalized Ratio (INR) is the preferred test for monitoring warfarin therapy.

The INR is calculated from the Prothrombin Time (PT) as follows:

\[(\text{Patient PT}/\text{Mean Normal PT})^{\text{ISI}}\]

The mean normal PT is the geometric mean of prothrombin times determined from at least 20 fresh samples obtained from healthy men and women. The International Sensitivity Index (ISI) is a measure of sensitivity of the thromboplastin. The manufacturer will frequently provide an ISI specific for the analyzer used. The ISI can be verified by the local laboratory using certified, reference plasmas (Clinical and Laboratory Standards Institute document H47-A2 One Stage Prothrombin Time [PT] Test and Activated Partial Thromboplastin Time [APTT] Test, 2008 [R]).

Limitations of INR

There are several recognized limitations of the test, including instrumentation effect on the ISI and erroneous reporting of the ISI by the thromboplastin manufacturer (Ansell, 2008 [R]).

Timing and frequency of INR testing

During initiation and maintenance therapy with warfarin, the INR is best measured at least 16 hours after the dose of warfarin.

In most stable patients, INR determinations can be obtained once or twice monthly. Per ACCP guidelines no more than 12 weeks should elapse between determinations. This is categorized as a 2B, weak recommendation, by the American College of Chest Physicians (American College of Chest Physicians, 2012 [R]).

Influence of Heparin and Lupus Anticoagulants on the INR

Prothrombin reagents contain a heparin neutralizer; however, presence of high concentrations of heparin in plasma samples (e.g., sample collected shortly after IV heparin bolus, or sample collected above an IV infusion of unfractionated heparin, or sample collected through a heparin-coated catheter [central venous line or arterial line]) will spuriously prolong the INR.

Prothrombin reagents contain a high concentration of phospholipid; thus, presence of lupus anticoagulants typically does not affect the INR result.

However, there are individual patients in whom lupus anticoagulants may spuriously prolong INR results obtained by some instrument-reagent combinations. In these patients, lupus anticoagulants can cause a prolongation of the PT and INR, resulting in a perceived overestimation of a patient's anticoagulation.

One study suggested that patients with a lupus anticoagulant might require a higher target therapeutic range than patients lacking a lupus anticoagulant; however, recent prospective studies do not confirm superiority of a higher target INR (Crowther, 2003 [A]).
Alternatives to INR in Patients with Lupus Anticoagulants

For patients with a prolonged baseline INR due to a lupus anticoagulant, alternatives to the INR have been evaluated. Measurement of chromogenic factor X levels or factor II levels may be helpful in the monitoring of warfarin therapy in selected patients with lupus anticoagulant (Fairweather, 1998 [R]; Moll, 1997 [D]). Both the chromogenic factor X and factor II levels may not be readily available.

Transitioning from Argatroban to Warfarin

Argatroban significantly prolongs the INR, requiring additional coagulation testing during transition to warfarin. Please refer to Annotation #4.7b "Monitoring, Parenteral DTI," for further discussion.

Blood Samples

Patient samples should be collected in 109 mmol/L (3.2%) sodium citrate when INR testing is performed on anticoagulated plasma (Fairweather, 1998 [R]; Adcock, 1997 [B]).

- The volume of sodium citrate in blood tubes used for collection of plasma INR testing should be adjusted when the patient's hematocrit is greater than 55%. Specimens with a high hematocrit will cause spuriously high INR values unless the citrate volume is adjusted (NCCLS, 2003 [R]).

- Anticoagulated whole blood may be stored spun or unspun at room temperature for up to 24 hours prior to testing (Fairweather, 1998 [R]).

Instruments Including Point-of-Care Instruments

Point-of-care coagulation instruments using whole blood or plasma specimens can be utilized for INR testing. Accuracy and precision data should be evaluated when selecting one of these instruments. INR values outside of the therapeutic range (2.0-3.0) obtained using a whole blood, fingerstick method may show significant bias when compared to plasma-based INR results obtained on laboratory instruments.

INRs obtained simultaneously on the same blood sample using point-of-care and laboratory instruments will not be identical due to differences in reagents, testing methods and specimen type.

An adequate quality program should be developed and followed for all whole blood testing.

If more than one testing method is used to follow warfarin therapy, comparative studies should be performed, and the results made available to the testing and treating practitioners (Ansell, 2008 [R]; Fairweather, 1998 [R]).

Accuracy of a point-of-care instrument can diminish over time due to changes in reagents, aging of the detection system, and poor maintenance. Periodic accuracy checks with the laboratory coagulation analyzer are indicated.

Each point-of-care instrument should be evaluated to determine the range of accurate INR results (reportable range). INR results outside this range should be confirmed in the laboratory.

Reagents

Sensitive thromboplastins (ISI values between 0.9 and 1.7) and reagent/instrumentation combinations for which the ISI has been established are recommended for INR testing (Ansell, 2008 [R]). Thromboplastins with ISI values near 1.0 are preferred. Sensitive thromboplastin reagents potentially improve the precision of the INR test and broaden the range of PT ratios corresponding to a therapeutic INR (Fairweather, 1998 [R]).
1.8. Correction of Supratherapeutic Anticoagulation/Reversal, Warfarin

Supratherapeutic anticoagulation may occur with patients taking warfarin. Vitamin K may be used to reverse the effects of warfarin; however, vitamin K can lead to warfarin resistance and subsequently, to an increased risk of thromboembolism.

One must weigh the benefits of reversing anticoagulation with warfarin and associated decreased risk for bleeding against the risk of vitamin K-induced warfarin resistance and associated increased risk for thromboembolism. The ACCP guidelines recommend against the routine use of vitamin K in patients taking warfarin with INRs between 4.5 and 10 with no evidence of bleeding. This is categorized as a 2B, weak recommendation, by the American College of Chest Physicians (American College of Chest Physicians, 2012 [R]). Patients taking warfarin with INRs greater than 10.0 and with no evidence of bleeding, the CHEST guidelines recommend oral vitamin K. This is categorized as a 2C, weak recommendation, by the American College of Chest Physicians (American College of Chest Physicians, 2012 [R]).


Important Considerations for Vitamin K Dosing

In an outpatient clinic setting, oral vitamin K is the preferred route of administration.

In a hospital setting, when patients are ill or taking nothing by mouth, intravenous vitamin K may be the preferred route of administration. To avoid anaphylactic reactions, vitamin K should be given over 30 minutes in a mixture of D5W 50 mL under monitored conditions. It is not necessary to premedicate with corticosteroids or antihistamines.

Administration of vitamin K by subcutaneous or intramuscular injections is not recommended due to unpredictable absorption, which can lead to erratic correction of INR and resistance to warfarin (Ansell, 2008 [R]; Shields, 2001 [B]; Whitling, 1998 [C]).
Table 7: Correction of Supratherapeutic Anticoagulation Caused by Warfarin

<table>
<thead>
<tr>
<th>Bleeding Severity</th>
<th>INR</th>
<th>Warfarin</th>
<th>Vitamin K</th>
</tr>
</thead>
<tbody>
<tr>
<td>No significant bleeding</td>
<td>4.5-10</td>
<td>Omit 1-2 doses and decrease dose</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If rapid reversal is required because of urgent surgery, may give ≤ 5 mg by mouth</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If INR is still high, can give additional 1-2 mg by mouth</td>
</tr>
<tr>
<td>Serious bleeding at any elevation of INR</td>
<td>NA</td>
<td>Hold, give intravenous vitamin K and supplement with FFP*, PCC** or rVIIa</td>
<td>5-10 mg IV by slow infusion; may repeat every 12 hrs</td>
</tr>
<tr>
<td>Life-threatening bleeding</td>
<td>NA</td>
<td>Hold, give intravenous vitamin K and supplement with FFP*, PCC** or rVIIa</td>
<td>5-10 mg IV by slow infusion; repeat if necessary depending on INR</td>
</tr>
</tbody>
</table>

FFP=fresh frozen plasma  PCC=prothrombin complex concentrate  rVIIa=recombinant factor VIIa

Vit K, available as 5 mg tab, IV solution
*FFP units average 250-275 mL. Administer 15 cc/kg FFP, round to the nearest unit.
** CHEST Guidelines recommends Four-Factor Prothrombin Complex Concentrate rather than plasma. Four-Factor Prothrombin Complex Concentrate is not available in the U.S.

(American Academy of Chest Physicians, 2012 [R])

1.9. Patient Education, Warfarin

Mechanism of action of warfarin: it depletes certain coagulation factor proteins in the blood.

Time of day to take warfarin: it should be taken at approximately the same time each day. Due to the short half-life of factor VII and its influence on the INR, this is especially important if the patient will have an INR drawn the next morning.

Explanation of INR, target range and regular testing.

Signs and symptoms of bleeding and that the provider should be contacted immediately if bleeding signs are present.

Need to notify provider if illness, injury or change in physical status occurs.

Need to inform all health care providers of anticoagulation therapy, especially if potentially undergoing an invasive procedure, surgery or dental work.

Drug interactions:

- What to do if a new medication is initiated or a medication is discontinued, especially if the interaction with warfarin is unknown: check INR within three to four days.
- Drugs that affect the absorption of warfarin.
• Drugs that increase or decrease the effect of warfarin.
• Common over-the-counter medication interactions including aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, natural or herbal remedies, laxatives, antacids, and multivitamin preparations containing vitamin K.

Role of vitamin K and the importance of consistency of vitamin K-rich foods in the diet rather than avoidance of vitamin K-rich foods.

Importance of minimizing trauma risk associated with activities at high risk for injury.

Effect of exercise: increased activity results in decreased effect of the drug.

Effect of personal habits: alcohol, chewing tobacco, etc.

Effect of certain conditions: congestive heart failure, thyroid disease, gastroenteritis and diarrhea.

Importance of self-monitoring: maintain a log of INRs, dose of warfarin, etc.

MedicAlert® bracelet/necklace and warfarin ID card.

2. Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparin (LMWH)

2.0 Introduction, UFH and LMWH

In October 2009 the FDA notified health care professionals of a change to heparin that standardized the USP unit dose with the WHO International Standard unit dose. This change resulted in an approximately 10% reduction in anticoagulant activity compared to heparin prepared using the previous USP Monograph potency. The FDA recommends that health care professionals "exercise clinical judgment in determining the dose of heparin for a patient and consider the clinical circumstances where the potency decrease may require dosage adjustments and more frequent monitoring," particularly when heparin is administered as a bolus intravenous dose and an immediate anticoagulant effect is clinically important. Due to the high inter-patient variability in heparin clearance (+/- 1.18 mL/min/kg) (Bauer, 2001 [R]), therapeutic heparin dose is highly individualized per patient and highly reliant on PTT or heparin assay monitoring and dose adjustment. Although a small downward bias may be observed overall, built-in PTT/ACT protocols and bolus dose ranges may negate the need for broad, empiric policy change.

Heparin’s (UFH, LMWH) anticoagulant effect is due to the presence of a pentasaccharide sequence, which potentiates the action of antithrombin leading to inactivation of several clotting factors – primarily factors Xa and IIa. Heparins have relatively rapid onset of action compared to warfarin and are often the first drug used in acute thrombotic situations.

UFH has variable absorption, metabolism, pharmacokinetics and effects on anticoagulation. Monitoring is required in most patients treated with this drug.

LMWHs are depolymerized by-products of UFH. Pharmacological advantages of LMWH relate to superior absorption and consistent dose effect response.
2.1. Adverse Effects, Including Heparin-Induced Thrombocytopenia, of UFH and LMWH

Key Points:

- Heparin-induced thrombocytopenia (HIT) should be suspected in patients who develop a skin lesion reaction at the injection site, have a systemic reaction to a bolus administration of heparin, or develop a greater than 50% decrease in platelet count from baseline labs while on heparin (Warkentin, 2007 [R]).

- HIT should be suspected if the patient experiences a new thrombotic event within 5 to 14 days of initiating heparin therapy, even if the heparin has been discontinued (Warkentin 2008a [R]).
  - In non-cardiac post-surgical patients, HIT should be suspected when the platelet count falls 50% from the postoperative platelet count peak (Warkentin, 2007 [R]).
  - Following cardiac surgery, the following two patterns are concerning for HIT:
    1) Drop in platelet count beginning greater than four days postoperatively (day of surgery = day 0)
    2) Thrombocytopenia that persists for greater than four days after surgery (American Academy of Chest Physicians, 2012 [R])

- All heparin should be stopped in patients suspected of having HIT until antibody test results are available.

- If the patient is on concomitant warfarin, and heparin-induced thrombocytopenia is suspected, the warfarin should be stopped, the warfarin effects corrected with vitamin K, and the patient started on direct thrombin inhibitor therapy.

Bleeding

Risk of bleeding increases with treatment-related factors such as dose, duration and use of thrombolytics and/or antiplatelet agents, and patient-related factors including age over 70 years, recent trauma or surgery, coagulopathy, peptic ulcer, neoplasm or renal failure.

The rate of major bleeding associated with 5-10 days of IV unfractionated heparin in patients with acute venous thromboembolism (VTE) is 0-7.0% and the rate of fatal bleeding 0-2.0%. The rate of major bleeding associated with 5-10 days of subcutaneous low-molecular-weight heparin in patients with acute VTE is 0.0-0.8%. There is no increased risk of bleeding associated with short-term IV unfractionated heparin and subcutaneous low-molecular-weight heparins in patients with unstable angina (Hirsh, 2004 [R]; Levine, 2004 [R]; Campbell, 1996 [A]; Hull, 1990 [A]).

Heparin-Induced Thrombocytopenia (HIT)

HIT is an immune-mediated reaction to heparins. It occurs in 2-3% of patients treated with UFH and less than 1% of patients treated with LMWH. This syndrome can be associated with paradoxical increased risk for venous and arterial thrombosis. Patients who develop HIT without associated thrombosis will have a significant risk for thrombosis in the subsequent 100 days. Patients with a history of HIT should not be treated with UFH or LMWH (Warkentin, 2003 [R]).
HIT should be suspected in patients who develop a skin lesion reaction at the injection site, have a systemic reaction to a bolus administration of heparin, or develop a greater than 50% decrease in platelet count from baseline labs while on heparin. HIT should also be suspected if the patient experiences a new thrombotic event within 5 to 14 days of initiating heparin therapy, even if the heparin has been discontinued (Warkentin 2008a [R]).

In the first 72 hours following the procedure, however, post-cardiac surgery patients frequently show a 40 to 50% decrease in the platelet count that persists beyond postoperative day five. Furthermore, 25-70% of these patients will develop antiplatelet factor 4 (PF4)-heparin antibodies, the causative agent in HIT. Only a small percentage of these antibody-positive patients with early, persistent and stable thrombocytopenia will develop clinical HIT. Further study correlating the strength of anti-PF4-heparin antibody assays, platelet activation assays and clinical outcomes of this group of patients is required before development of definitive recommendations (Gruel 2010 [R]; Selleng, 2010 [D]).

Delayed-onset HIT is an increasingly recognized form of this disorder. Patients with delayed-onset HIT typically present with thromboembolic complications one to two weeks (studies show the range 5 to 40 days) after receiving their last dose of LMWH or UFH. They frequently display mild or moderate thrombocytopenia. When HIT is not recognized as the etiology of the thromboembolic complication, the patient is frequently rechallenged with heparin, causing significant worsening of the thrombosis, as well as the thrombocytopenia. These patients typically have very high titers of HIT-related antibodies. The possibility of delayed onset HIT should be considered in any patient presenting with thromboembolism after a recent hospitalization.

Patients suspected of having any form of HIT should have their heparin stopped while antibody testing for HIT is performed. Patients with a high clinical probability of having HIT should be treated with an appropriate alternative anticoagulant before antibody test results are available. Direct thrombin inhibitors (DTIs) are the alternative anticoagulant of choice for patients with HIT. Three generics are FDA approved: argatroban, lepirudin (lepirudin will no longer be manufactured after May 2013) and most recently, bivalirudin (Warkentin, 2004a [R]; Warkentin, 2004b [R]; Warkentin, 2003 [R]).

The off-label use of fondaparinux has been suggested as an alternative to DTI therapy in HIT, given its long half-life and lack of significant effect on the INR as well as the Protein C pathway (Warkentin, 2010 [R]). Although fondaparinux therapy can result in development of anti-PF4/heparin antibodies, they usually do not result in platelet activation. Three cases of HIT related to fondaparinux therapy have been reported (Rota, 2008 [D]; Warkentin, 2008 [D]; Warkentin, 2007 [D]). Further study is required prior to recommendation of fondaparinux as a therapy in HIT.

There is no data to support use of the new oral anticoagulants like dabigatran or rivaroxaban in HIT (American Academy of Chest Physicians, 2012 [R]).

Warfarin therapy alone is contraindicated in the setting of acute HIT (Warkentin, 2010 [R]). If a patient is receiving warfarin when there is a high clinical probability of HIT, the warfarin should be stopped. The warfarin effect should be reversed with vitamin K, and DTI therapy should be initiated. Studies have demonstrated that the manufacturer-recommended dosages for argatroban are too high. Therefore, lower doses are recommended (see Annotation #4.6b, "Dosing, Parenteral DTI"). Low maintenance doses of warfarin can be restarted during DTI therapy after the platelet count has significantly improved and there is clinical improvement in the patient’s thrombosis. There should be at least a five-day overlap of the DTIs and warfarin. The DTI therapy should be continued until the platelet count stabilizes (Warkentin, 2004b [R]).

Please refer to Annotations #4.0-4.9b, "Direct Thrombin Inhibitors (DTI)," for more information.
2.2. Contraindications, UFH and LMWH

- Active major bleeding, including intracerebral hemorrhage within past two weeks, subarachnoid hemorrhage until definitively treated.
- Thrombolytics given within past 24 hours for acute stroke.
- Hypersensitivity to heparin or pork products.
- Heparin-induced thrombocytopenia (HIT). Patients with a history of HIT who require cardiac surgery may receive unfractionated heparin for the procedure if they are antibody-negative for platelet factor 4 (PF4). Alternate anticoagulants should be used for preoperative and postoperative anticoagulation (Warkentin, 2007b [R]).

2.3. Precautions, UFH and LMWH

Active or recent history of gastrointestinal ulceration and hemorrhage

Bacterial endocarditis

Bleeding diathesis

Concomitant therapy with agents that inhibit platelets

Congenital or acquired bleeding disorders

Hemorrhagic stroke

Status post brain, spinal or ophthalmologic surgery

Uncontrolled arterial hypertension

Diabetic retinopathy

Impaired renal function (CrCl < 50 mL)

Obese patients: Dose capping is not recommended and twice daily dosing may be preferable for Lovenox.

<table>
<thead>
<tr>
<th>CrCl via Cockroft-Gault</th>
<th>Dalteparin</th>
<th>Enoxaparin</th>
</tr>
</thead>
<tbody>
<tr>
<td>CrCl 30-50 mL/min</td>
<td>No accumulation occurs and no dosing adjustment is recommended, per the package insert.</td>
<td>A 15-20% accumulation occurs with &gt; 14 day use. No dosing adjustment is recommended, per package insert.</td>
</tr>
<tr>
<td>CrCl &lt; 30 mL/min</td>
<td>No accumulation has been demonstrated for up to one week. Package insert recommends: use with caution.</td>
<td>A 40-50% accumulation occurs. Per package insert, reduce prophylactic doses to 30 mg subcutaneous once daily and treatment doses to 1 mg/kg subcutaneous once daily.</td>
</tr>
</tbody>
</table>

(Ansell, 2008 [R])
2.4. Pregnancy, UFH and LMWH

Adverse Effects in Pregnancy

UFH and LMWH do not cross the placenta and therefore do not cause teratogenicity or fetal bleeding, though bleeding at the uteroplacental junction is possible (Bates, 2004 [R]).

Patients with mechanical heart valves who are pregnant are at high risk and should be managed by an anticoagulation expert. A study has shown that two pregnant patients with mechanical heart valves had thrombotic complications when treated with LMWH. Because of this, the FDA and the manufacturer have warned that enoxaparin is not presently indicated for use in prophylaxis for heart valve patients who are pregnant. However, the available data sets, clinical trials, reviews and registry data suggest that, compared with UFH, LMWHs may be safe and effective agents in pregnant women with mechanical heart valves (Seshadri, 2005 [M]).

The ACCP recommends that women requiring long-term anticoagulation with warfarin who are attempting pregnancy be monitored with frequent pregnancy tests. They recommend substituting UFH or a LMWH for warfarin when pregnancy is achieved (Bates, 2004 [R]). LMWHs cause less HIT and bone loss during pregnancy than UFH.

The pharmacokinetics of LMWH in pregnancy are significantly altered. Consideration should be given to monitoring the anti-Xa activity at 12-15 weeks and 30-33 weeks.

When possible, patients using UFH or a LMWH should have a planned delivery. UFH should be discontinued six hours prior to a planned delivery. LMWH should be discontinued 24 hours prior to a planned delivery.

2.5. Breastfeeding, UFH and LMWH

Heparin is not secreted in breast milk and can be given safely to nursing mothers (Bates, 2004 [R]).

2.6. Dosing

2.61. UFH Dosing

Anaphylaxis occurs in 1% of patients who have previously received protamine (such as NPH insulin). Other adverse effects include hypotension.

(Hirsh, 2004 [R])

Testing should be obtained before initiation of UFH:

- Complete blood count (CBC)/Platelet count
- INR
- APTT
- Creatinine

Obtain if there is clinical suspicion of abnormal results based on patient history and physical:

- Liver enzymes (ALT, AST, GGT)
- Albumin
2.6. LMWH Dosing

**Key Point:**
- Prophylactic doses are lower than therapeutic and carry lower bleeding risks. However, in patients with acute thrombosis and cardioembolic risks, therapeutic dosing is generally recommended.

**Testing should be obtained before initiation of LMWH:**
- Complete blood count (CBC)/Platelet count
- INR
- aPTT
- Creatinine

Return to Table of Contents
Obtain if there is clinical suspicion of abnormal results based on patient history and physical:

Liver enzymes (ALT, AST, GGT)
Albumin

LMWH should not be administered by intramuscular injection. Therapeutic doses of a LMWH are different from prophylactic doses. Doses of different LMWHs are not interchangeable (Burnett, 1998 [R]; Weitz, 1997 [R]; Frydman, 1996 [R]). The anticoagulant effect of LMWH can extend beyond 24 hours after administration.

The dose should be modified for patients with impaired renal function. It may be necessary to monitor the anti-Xa level in these patients. LMWHs are relatively contraindicated in patients with a creatinine clearance less than 30 mL/min or who are receiving dialysis.

The optimal dose of LMWH has not been established in patients with low body weight (less than 50 kg) (possibly higher than usual dose), obesity (possibly lower than usual dose) or pregnancy (changing dose due to changing creatinine clearance). It may be necessary to monitor the anti-Xa level in these patients (Gerlach, 2000 [D]).

Prophylactic doses of the low-molecular-weight heparins are less than therapeutic doses and carry lower bleeding risks. However, in patients with acute thrombosis or increased thrombosis risk, therapeutic dosing is generally necessary.

Please see the disease specific ICSI guideline recommendations on the ICSI Web site:

- Diagnosis and Initial Treatment of Ischemic Stroke
- Diagnosis and Treatment of Chest Pain and Acute Coronary Syndrome (ACS)
- Venous Thromboembolism Diagnosis and Treatment
- Venous Thromboembolism Prophylaxis

2.7. Monitoring

2.7.1. UFH Monitoring

UFH treatment of thrombosis can be monitored using an aPTT or heparin assay. The recommended test for monitoring UFH, including the therapeutic range for the test, should be provided by the laboratory. Of note, aPTT results vary among institutions due to differences in laboratory instruments and reagents. The aPTT therapeutic range should correspond to a plasma heparin concentration of 0.3 to 0.7 units/mL by an anti-Xa inhibition assay (0.2 to 0.4 units/mL by protamine titration assay) (Brill-Edwards, 1993 [R]).

Heparin assays are being increasingly used for monitoring UFHs in the treatment of venous thromboembolism. The suggested target therapeutic range is 0.35 to 0.7 units/mL by the anti-Xa inhibition assay. Monitoring unfractionated heparin using a heparin assay may be indicated when the expected aPTT prolongation is not observed despite high doses of UFH (greater than 35,000 units unfractionated heparin in 24 hours), when the pretreatment aPTT is prolonged or when a lupus anticoagulant has been previously documented in the patient (Hirsh, 2004 [R]; Olson, 1998 [R]).

Patients receiving UFH or a LMWH should be monitored for heparin-induced thrombocytopenia (HIT). A platelet count of less than 50% of baseline or the postoperative peak during heparin therapy may indicate the development of HIT. The recommended frequency of monitoring is dependent upon the patient's risk of developing HIT. Postoperative patients receiving prophylactic or therapeutic UFH have the highest risk
of HIT, requiring platelet monitoring every other day from day 4 to 14 or until the heparin is discontinued. Any patient receiving therapeutic UFH, medical and obstetrical patients receiving prophylactic UFH, medical and obstetrical patients receiving LMWH after a dose of UFH, postoperative patients receiving prophylactic LMWH, and postoperative/critical care patients receiving UFH flushes are at lower risk for developing HIT, but still warrant every-other-day platelet count monitoring between day 4 and 14 or until the heparin is discontinued.

Medical and obstetrical patients receiving LMWH, medical patients receiving UFH flushes and patients receiving therapeutic or prophylactic fondaparinux are at very low risk of developing HIT, and routine platelet count monitoring is not needed. Patients receiving outpatient heparin therapy should be instructed to seek immediate medical attention if the signs or symptoms of HIT develop.

Patients who have been exposed to heparin within the past 100 days and patients with unclear heparin exposure histories should undergo baseline platelet count testing, with repeat platelet count testing within 24 hours of the first heparin dose to evaluate the possibility of rapid-onset HIT.

See Annotation #2.1, "Adverse Effects, Including Heparin-Induced Thrombocytopenia, of UFH and LMWH," for more information.

(Hirsh, 2008 [R])

2.72. LMWH Monitoring
Patients receiving LMWH are at lower risk of developing HIT than patients receiving UFH. The need for platelet count monitoring during LMWH therapy depends on the indication for anticoagulation. Postoperative patients receiving LMWH and medical/obstetrical patients receiving LMWH following at least one dose of UFH (including UFH IV flushes) within the past 100 days infrequently experience HIT. Therefore, a baseline platelet count followed by platelet counts every two to three days is recommended until the LMWH is discontinued or until day 14 of therapy, whichever comes first.

Medical and obstetrical patients receiving only LMWH rarely develop HIT. After a baseline platelet count, routine platelet count monitoring is not required. If there is clinical uncertainty about whether the patient may have received UFH, community standard is to monitor platelet counts monthly.

All patients receiving any form of heparin should be instructed to immediately seek medical attention if signs or symptoms of venous thromboembolism are suspected (Warkentin, 2004a [R]).

2.8. Correction of Supratherapeutic Anticoagulation/Reversal

2.81. UFH, Correction of Supratherapeutic Anticoagulation/Reversal
Protamine sulfate administered by slow IV infusion over 10 minutes reverses the anticoagulation effects of unfractionated heparin.

Bolus dose of UFH (units) divided by 100 = protamine dose

Hourly infusion rate of UFH (units) divided by 40 = protamine dose

2.82 LMWH, Correction of Supratherapeutic Anticoagulation/Reversal
No agent, including fresh frozen plasma (FFP) and vitamin K, is effective for complete reversal of supratherapeutic anticoagulation with LMWH. Reversal of LMWH with protamine sulfate is incomplete, with neutralization of 60-75% at most. However, protamine should be considered for patients with severe
life-threatening bleeding. Anaphylaxis occurs in 1% of patients who have previously received protamine (such as NPH insulin). Other adverse effects include hypotension (Hirsh, 2004 [R]).

Administering protamine slowly can minimize adverse reactions to protamine, such as hypotension or bradycardia (Hirsh, 2004 [R]). Note: Excessive protamine doses may worsen bleeding potential (Lacy, 2008 [R]).

If LMWH has been administered within the last eight hours (unlabeled use):

**Enoxaparin**
- First dose: 1 mg protamine for each 1 mg of enoxaparin. Administered by slow IV infusion over 10 minutes (Trissel, 2005 [R])
- Second dose: 0.5 mg protamine for each 1 mg enoxaparin. Administered by slow IV infusion over 10 minutes. Do not exceed 50 mg in 10 minutes (Trissel, 2005 [R])

**Dalteparin**
First dose: 1 mg protamine for each 100 anti-Xa units of dalteparin. Administered by slow IV infusion over 10 minutes. Do not exceed 50 mg in any 10 minutes (Trissel, 2005 [R]).

Smaller doses are needed if the LMWH was administered more than eight hours prior.

### 2.9. Patient Education

#### 2.91. UFH, Patient Education
Importance of understanding heparin assays, INRs and target ranges.
Know and watch for signs of bleeding.

#### 2.92. LMWH, Patient Education
Over-the-counter and prescription drugs that should not be taken while on LMWH.
Importance of understanding heparin assays, INRs and target ranges.
Know and watch for signs of bleeding.
Proper technique for injecting LMWH.
Restrictions for other conditions including deep vein thrombosis, stroke or stable coronary artery disease. Please refer to related ICSI guidelines for more information.
Importance of adhering to prescribed regimen.
Tables of patient education resources, along with patient- and provider-oriented Web sites, are included in the Implementation Tools and Resources Table.

### 3. Synthetic Pentasaccharide (Fondaparinux)

#### 3.0. Introduction, Synthetic Pentasaccharide
Fondaparinux is a synthetic compound composed of the essential pentasaccharide sequence that selectively inhibits factor Xa.
3.1. Adverse Effects, Synthetic Pentasaccharide
Anemia has been reported in some patients receiving fondaparinux. Asymptomatic elevation in AST and ALT associated with an increase in bilirubin can occur in a small percentage of patients.

3.2. Contraindications, Synthetic Pentasaccharide
Active major bleeding including intracerebral hemorrhage within past two weeks, subarachnoid hemorrhage until definitively treated.
Bacterial endocarditis.
Severe renal impairment defined by CrCl (Cockroft-Gault) < 30 mL/minute.
Secondary increased risk for major bleeding episodes.
Thrombolytics given within past 24 hours for acute stroke.
Fondaparinux has a long elimination half-life and there is no antidote for reversal; therefore, patients who may require rapid reversal are not candidates for this therapy.

3.3. Precautions, Synthetic Pentasaccharide
Fondaparinux should be administered according to recommended regimen, especially with respect to timing of the first dose after surgery.
In hip fracture, hip replacement, knee replacement or abdominal surgery, clinical studies show that the administration of fondaparinux before six hours after surgery has been associated with increased risk of major bleeding.

Precautions:
- Active or history of recent gastrointestinal ulceration and hemorrhage.
- Bleeding diathesis.
- Concomitant therapy with agents that inhibit platelets.
- Congenital or acquired bleeding disorders.
- Fondaparinux is not recommended for patients with platelets less than 100,000/mm³.
- Hemorrhagic stroke.
- Status recent post brain, spinal or ophthalmologic surgery.
- Uncontrolled arterial hypertension.
- Diabetic retinopathy.
- Needle guard of the prefilled syringe contains dry natural latex rubber; it is possible but not necessary for the administration that the needle guard may come in contact with the patient and pose an allergy risk.
- Renal impairment (CrCl 30-50 mL/min).

3.4. Pregnancy, Synthetic Pentasaccharide
The safety of fondaparinux in pregnant women is unknown. Limited clinical experience suggests that fondaparinux may cross the placental barrier, resulting in low but measurable anti-Xa activity in the umbilical cord (Weitz, 2004 [R]).
Studies performed in pregnant rats and rabbits have not shown impairment of fertility or a teratogenic effect on the fetus, resulting in the drug being classified as "class B." Only a few case reports of use during pregnancy have published in the scientific literature (Gerhardt, 2007 [D]; Harenberg, 2007 [D]; Mazzolai, 2006 [D]). Safety of the drug in nursing women has also not been studied to date, although, again, in lactating rats, only a small amount was found in breast milk.

3.5. Breastfeeding, Synthetic Pentasaccharide

Animal studies have shown secretion of fondaparinux in breast milk. It is unknown if humans secrete fondaparinux in breast milk.

3.6. Dosing, Synthetic Pentasaccharide

Testing should be obtained before initiation of fondaparinux:

- Complete blood count (CBC)/Platelet count
- INR
- aPTT
- Creatinine

Obtain if there is clinical suspicion of abnormal results based on patient history and physical:

- Liver enzymes (ALT, AST, GGT)
- Albumin

Therapeutic doses are different than prophylactic dosing.

The optimal dose of fondaparinux has not been established in patients with obesity (possibly lower than usual dose). It may be necessary to monitor the anti-Xa level in these patients (Gerlach, 2000 [D]).

### Table 8. FDA Approval Status, Indications and Dosing of Fondaparinux

<table>
<thead>
<tr>
<th>FDA-Approved Indication (Adult)</th>
<th>Fondaparinux</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hip-fracture surgery, hip/knee replacement surgery, abdominal surgery</td>
<td>2.5 mg subcutaneous every 24 hrs</td>
</tr>
<tr>
<td>Therapy for deep vein thrombosis including pulmonary embolism</td>
<td>Less than 50 kg, 5 mg subcutaneously every 24 hrs</td>
</tr>
<tr>
<td></td>
<td>50-100 kg, 7.5 mg subcutaneously every 24 hrs</td>
</tr>
<tr>
<td></td>
<td>More than 100 kg, 10 mg subcutaneously every 24 hrs</td>
</tr>
</tbody>
</table>


Please refer to the ICSI Venous Thromboembolism Diagnosis and Treatment and Venous Thromboembolism Prophylaxis guidelines for more information.

3.7. Monitoring, Synthetic Pentasaccharide

The heparin assay (anti-Xa) has been used to monitor effects of fondaparinux; however, in most clinical situations, monitoring may not be necessary. Indications for monitoring of fondaparinux include patients weighing over 180 kg or those in whom the level of anticoagulation needs to be checked prior to a procedure.

A platelet count should be obtained prior to the initiation of fondaparinux. Antibodies to fondaparinux rarely interact with platelet factor 4. There are rare reports of HIT associated with fondaparinux (Warkentin, 2010 [R]). Fondaparinux is not recommended for patients with platelets less than 100,000/mm³ due to the overall increased risk of bleeding.
Fondaparinux may cause transient elevations in serum aminotransferases. This effect is reversible and routine monitoring is not recommended.

Additional information on fondaparinux is included in the ICSI Venous Thromboembolism Prophylaxis guideline.

3.8. Correction of Supratherapeutic Anticoagulation/Reversal, Synthetic Pentasaccharide

There is no antidote for excessive bleeding due to fondaparinux. Recombinant factor VIIa (rFVIIa) has shown promise as a possible antidote in studies utilizing healthy volunteers. rFVIIa treatment can be complicated by thrombosis. Up to 7% of patients with acute intracerebral hemorrhage who received rFVIIa therapy experienced an adverse thromboembolic event (Crowther, 2008 [R]; Mayer, 2007 [A]). Enzymes capable of degrading heparin have also been investigated as a future treatment for excessive bleeding due to fondaparinux.

(Weitz, 2004 [R]; Bijsterveld, 2002 [A]; Warkentin, 2002 [R]; Yu, 2000 [NA])

3.9. Patient Education, Synthetic Pentasaccharide

Importance of understanding fondaparinux.

Know and watch for signs of bleeding.

Proper technique for injecting fondaparinux.

Restrictions for other conditions including deep vein thrombosis, stroke or coronary artery disease. Please refer to related ICSI guidelines for more information.

Importance of adhering to prescribed regimen.

4. Direct Thrombin Inhibitors (DTI)

4.0. Introduction, DTI

Direct thrombin inhibitors (DTIs) – argatroban, bivalirudin, lepirudin, dabigatran – are a relatively new class of anticoagulant drugs. (Lepirudin will no longer be manufactured after May 2013.) They exert their anticoagulant effect by directly attaching to and inhibiting both free and fibrin-bound thrombin. Potential advantages of these drugs over UFH are inhibition of fibrin (clot)-bound thrombin, a more predictable anticoagulant response, and no effect on platelet factor 4. Parenteral direct thrombin inhibitors have been available for nearly a decade and are used most frequently in cardiovascular procedures and for the treatment of patients with heparin induced thrombocytopenia. The oral direct thrombin inhibitor, dabigatran, was recently FDA approved for use in patients with non-valvular atrial fibrillation.

Consultation with a hematologist or anticoagulation expert may be helpful when using these new anticoagulant drugs because of both drug and disease complexities.

4.0a. Key Considerations for Dabigatran

- FDA approved for use only in non-valvular atrial fibrillation as an alternative to warfarin for stroke prevention. (Wann, 2011 [R])
• Patients most likely to benefit from dabigatran are patients unable to achieve and sustain a stable INR or those unable to use warfarin due to management issues (Wallentin, 2010 [A]).

• Like warfarin, it requires the same careful risk/benefit assessment for patients at great risk for hemorrhage (Stangier, 2009 [R]).

• Caution should be used in patients with CrCl < 30 mL/min as drug accumulation will occur and there is no clinical experience in this patient population (Stangier, 2009 [R]).

• Prior to procedures the drug must be held, the duration of which depends on a patient's renal clearance and bleed risk from procedure (van Ryn, 2010 [R]).

Dabigatran is rapidly absorbed, with peak dabigatran levels achieved within two to four hours. The bioavailability of dabigatran following oral administration of dabigatran etexilate is between 3 and 7%. The half-life of dabigatran is 12-17 hours, and steady-state concentrations are reached within two to five days after multiple doses. Dabigatran is renally eliminated so clearance is significantly influenced by renal function.

Product care information

Dabigatran deteriorates quickly when exposed to humidity and must be kept in its original package to keep dry. Dabigatran is manufactured in bottles of 60 capsules (a 30-day supply) or in blister packs sealing each capsule separately. Bottles from the manufacturer contain a dessicant in the lid to ensure stability for 90 days after opening. Capsules packaged in bottles should be kept tightly closed and should NOT be placed in any other container, such as weekly dosing containers used to enhance adherence, as such containers cannot guarantee moisture resistance. Patients should be instructed to keep the product in its original container and close the cap tightly after each use.

4.1a. Adverse Effects, Dabigatran

Side Effects

Bleeding

Although overall bleed risk was similar to warfarin, there was a significantly higher incidence of gastrointestinal bleeding while a significantly lower incidence of intracranial hemorrhage in the patients taking dabigatran. Also demonstrated in a subgroup analysis was a trend toward a higher incidence of major bleeding in patients 75 years of age and older on dabigatran.

Dyspepsia

A significant (5.5%) number of patients in the trial experienced a severe form of dyspepsia on dabigatran. Elevation of ALT or AST greater than three times the upper limit of normal was similar for both doses of dabigatran and warfarin.

Myocardial infarction

The RE-LY trial also demonstrated a statistically significant increase in the rate of myocardial infarction in patients treated with dabigatran (0.7% per year) as compared to a rate of 0.5% per year in patients treated with warfarin. This translated into a relative risk of 1.38 (95% confidence interval, 1.00-1.91; P=0.048). Further analysis (Lip, 2010 [A]) was undertaken by reviewing pooled data from multiple trials, the largest being RE-LY, to look at this effect. The analysis revealed that among patients with atrial fibrillation, warfarin may result in a lower risk of myocardial infarction. The data suggests there may be an intrinsic myocardial protective effect from warfarin as opposed to non-warfarin anticoagulants.
4.2a. Contraindications, Dabigatran

Active Pathological Bleeding

Patients with prohibitive bleed risks were not included in studies of dabigatran. As with all anticoagulants, extreme caution should be used in giving dabigatran to patients with bleeding diatheses, falls risk, alcohol abuse or compliance issues. An individual patient's risk of thrombosis versus risk of bleeding needs to be assessed before use of this or any anticoagulant.

Pregnant patients and those with valvular heart disease have not been studied and are not yet candidates for this drug.

Dose adjustment or avoidance of drug should be considered in patients with severe renal insufficiency, especially if the patient's kidney function is in flux.

4.3a. Precautions, Dabigatran

Drug Interactions

Similar to other anticoagulants, aspirin and other anti-platelet agents have been associated with a significant increase in risk for hemorrhagic complications. Unless strongly indicated anti-platelet agents should be avoided in patients taking dabigatran.

Dabigatran etexilate, the prodrug of dabigatran, is a p-glycoprotein substrate, and the active drug dabigatran is not. The absorption of the prodrug dabigatran etexilate can be altered by p-glycoprotein inhibitors and inducers. Drugs that inhibit p-glycoprotein (e.g., amiodarone, clarithromycin, diltiazem, verapamil) can increase the area under the drug plasma concentration curve (AUC) of dabigatran. Administering dabigatran more than two hours before a p-glycoprotein inhibitor may minimize the effect of the inhibitor on dabigatran absorption. Drugs that induce p-glycoprotein (e.g., rifampin) decrease the AUC of dabigatran. Separating the dose of dabigatran and a p-glycoprotein inducer is not thought to minimize the magnitude of the interaction. Therefore, the concomitant use of dabigatran and p-glycoprotein inducers should be avoided if possible (Horn, 2010 [X]).

Administration of dabigatran etexilate capsules with pantoprazole resulted in a reduction of dabigatran's AUC by 20-30% and its peak concentration by 45% (Horn, 2010 [X]; Stangier, 2008 [A], Trocóniz, 2007 [B]; Stangier, 2005 [B]). In the RE-LY trial, concomitant use of proton pump inhibitors and H2 receptor antagonists did not appreciably change the trough concentration of dabigatran (Connolly, 2009 [A]).

4.4a. Pregnancy, Dabigatran

Pregnancy Category C

There are no adequate and well-controlled studies in pregnant women.

4.5a. Breastfeeding, Dabigatran

It is not known whether dabigatran is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when dabigatran is administered to a nursing woman.

(package insert, as of February 2012)
4.6a. Dosing, Dabigatran

The FDA-approved dose of dabigatran for use in non-valvular atrial fibrillation is 150 mg twice daily for patients with creatinine clearance (CrCl) > 30 mL/min and 75 mg twice daily in patients with CrCl of 15-30 mL/min. The lower renal dose is based on pharmacokinetic data, and there is no clinical experience available. Use in patients with CrCl < 15 mL/min or patients receiving dialysis is not recommended. If a dose is missed, and the next dose is due within the next six hours, the patient should wait until the next scheduled dose. For example, if the 8:00 a.m. morning dose is missed, and the patient realizes this at 4:00 p.m., then it is recommended that the patient wait until the next dose at 8:00 p.m. However, if the patient realized at 11:00 a.m. that the 8:00 a.m. dose was missed, then the dose can be taken at 11:00 a.m.

Indications

Atrial fibrillation

A large randomized controlled open label trial (Randomized Evaluation of Long-Term Anticoagulation Therapy, RE-LY) compared dabigatran 150 mg twice daily to adjusted dose warfarin to achieve a target INR range of 2.0-3.0 in patients with atrial fibrillation and at least one additional risk factor for stroke. The primary objective of the study was to determine if dabigatran was non-inferior to warfarin at reducing stroke (ischemic or hemorrhagic) and systemic embolism. Dabigatran 150 mg twice daily was associated with a lower incidence of stroke (1.11%/year) compared to warfarin (1.69%/year) with similar hemorrhagic rates. Major bleeding occurred at a rate of 3.11% per year for dabigatran and 3.36% per year for warfarin.

A subgroup analysis of the RE-LY study demonstrated that the majority of the benefit of dabigatran was seen when compared to warfarin patients who were poorly controlled. These poorly controlled warfarin patients had the greatest proportion of bleeding and thrombotic complications.

Perioperative Management

Pre-Procedure Management

- The time interval between discontinuing dabigatran and surgical intervention is based on the risk of bleeding and the patient's renal function. This time interval will be longer in individuals with decreased renal function.
- In patients with normal renal function (creatinine clearance > 50 mL/min), discontinue dabigatran at least 24 hours prior to the procedure. However, for patients undergoing an intervention considered to have a high risk for bleeding, dabigatran should be discontinued two to four days prior to the intervention.
- For patients with estimated creatinine clearance between 30 to 50 mL/min, dabigatran should be discontinued at least 48 hours before the procedure; for high bleeding risk situations, dabigatran should be discontinued at least four days before the procedure.
- For patients with estimated creatinine clearance less than 30 mL/min, dabigatran should be discontinued for at least five days or longer.
- In patients at high risk of bleeding, a thrombin time (TT) can be performed 6-12 hours prior to surgery. A normal TT indicates that no drug is present (van Ryn, 2010 [R]). However, the TT does not accurately reflect plasma dabigatran concentrations, so it is not useful in providing an estimate of risk for surgical hemorrhage.
Post-Procedure Management

- It should be noted that, unlike warfarin, the anticoagulant effect of dabigatran occurs within one hour (if taken on an empty stomach), or three hours (if taken with a meal) after drug ingestion (Dabigatran etexilate [Pradaxa] – a new oral anticoagulant, 2010 [NAJ]).
- Timing of resumption of dabigatran after the procedure needs to be tailored to the procedure and its postoperative bleed risk.

Bridging for Warfarin Patients

At present, there is no experience with the use of dabigatran as a bridging agent (to replace heparin products) for patients on chronic warfarin therapy undergoing procedures. Because of its effect on the INR, dabigatran could potentially interfere with the use of flexible dosing protocols used to establish warfarin dosing during initiation. Heparin products are considered the preferred anticoagulants to use with warfarin during these circumstances.

Cardioversion

In a subgroup analysis of patients who underwent cardioversion while participating in the RE-LY trial, dabigatran had a low incidence of stroke and major bleeding within 30 days of cardioversion and was comparable to warfarin patients. Dabigatran was considered a safe alternative to warfarin in patients requiring cardioversion (Nagarakanti, 2011 [A]).

4.7a. Monitoring and Effect on Laboratory Testing, Dabigatran

Routine monitoring of dabigatran is not required. Specialized laboratory assays (ecarin clotting time, ECT; dilute thrombin time, dTT) are required for accurate assessment of plasma dabigatran levels; however these assays are not widely available. Dabigatran prolongs the clotting times of routine, more widely available assays (thrombin clotting time, TT; activated clotting time, ACT; prothrombin time, PT; activated partial thromboplastin time, aPTT). However, these assays do NOT reliably predict plasma dabigatran levels and do not provide an accurate assessment of risk of surgical hemorrhage in patients on dabigatran. The information provided by these assays is limited to whether there is residual dabigatran effect or not.

4.8a. Correction of Supratherapeutic Anticoagulation/Reversal, Dabigatran

NOTE: Consensus-based statements comprise the content of this section on dabigatran. It is important to note that, at the time of writing, there was little data to support these consensus-based recommendations.

Laboratory Testing and Dabigatran

Indications for laboratory testing:

Currently, therapeutic monitoring is not indicated.

Laboratory assays:

Laboratory assays may be broadly categorized into generally available tests and specialized laboratory assays.

- Generally available tests

These include a prothrombin time (PT), activated partial thromboplastin time (aPTT) and thrombin time (TT). Dabigatran prolongs these assays; however, the degree of prolongation does NOT reliably predict plasma dabigatran levels nor does it provide an accurate assessment of risk of surgical hemorrhage in patients on dabigatran. The information provided by these assays is limited to
whether there is residual dabigatran effect or not. **Note:** A normal PT or aPTT does not exclude the possibility of residual dabigatran. The thrombin time is typically very sensitive and, again, only provides information on presence or absence of residual drug.

- **Specialized laboratory assays**

  These include ecarin clotting time (ECT); dilute thrombin time (dTT) and activated clotting time (ACT). When appropriately calibrated, the ECT and dTT generally provide reliable information on plasma dabigatran levels; however these assays are not widely available. In addition there is currently no information on plasma dabigatran levels and risk of hemorrhage and/or the safety of surgical or other invasive interventions.

**Management of Bleeding**

- **There are limited options for management of bleeding on dabigatran as there is no antidote for reversal of the anticoagulation effect of dabigatran.**

- **If dabigatran was consumed within two hours of presentation, activated charcoal, at standard doses, should be considered (van Ryn, 2009 [R]).**

- **Hemodialysis is the only known intervention that reduces plasma dabigatran concentration. Approximately 60% of dabigatran is removed after four hours of dialysis (Stangier, 2010 [B]; Stangier, 2008 [A]). But, the dabigatran volume of distribution is 50-70 L, and a rebound increase in plasma levels of dabigatran may occur after hemodialysis. Thus, close observation and follow-up is needed given that the patient will likely need more dialysis.**

- **Fresh frozen plasma infusion will not reverse the anticoagulation effect of dabigatran, as the drug will inhibit thrombin in the transfused plasma. (It is important to note that the prolonged clotting times on dabigatran are a reflection of thrombin [factor II] inhibition and not a clotting factor deficiency.)**

- **As a last resort, one could consider use of procoagulant hemostatic agents such as recombinant factor VIIa (rFVIIa) activated or non-activated prothrombin complex concentrates (PCC). These have been shown to shorten clotting times in vitro and in the rat model; however, they did not reduce blood loss in the rat model (van Ryn, 2008 [R]). In healthy subjects, clotting times remained prolonged after PCC infusion, showing inadequate reversal of anticoagulation (Eerenberg, 2011 [A]).**

The ICSI work group has included recombinant activated factor VII (rFVIIa) or prothrombin complex concentrate as options to help with clot formation at the site of bleeding. They do not reverse the drug, the correct dose is unknown and there is no FDA approval for this use. Thrombosis is a known side effect of rFVIIa and PCC.

**Protocol for Management of Bleeding on Dabigatran**

**Consensus-Based Protocol for Bleeding Management**

**NOTE:**

- **Primary use would be in the emergency room and hospital settings where adult patients on dabigatran are bleeding.**

- **Consensus-based statements comprise the content of this section on dabigatran. It is important to note that, at the time of writing, there was little data to support these consensus-based recommendations.**

- **There is no specific agent to reverse the drug.**

- **Plasma will not reverse the drug as dabigatran will inhibit thrombin in transfused plasma.**
• The only way to remove the drug is dialysis, but this has limited efficacy.
• There is very little data to help guide us in managing bleeding complications on the drug.

**NOTE**
• All clotting times may be abnormal on dabigatran.
• Thrombin time (TT) is the most sensitive to the drug.
• Fibrinogen activity testing may not be reliable on dabigatran.
• Clotting times do not accurately reflect drug levels.

For minor bleeding
• Evaluate drug compliance, change in renal function, whether anatomical defects explain hemorrhage.
• Use local measures to control the bleeding.
• Keep hydrated.
• Replace fluids and blood products as needed.
• Clinical judgment to hold or continue dabigatran. Stopping the drug will decrease the bleeding risk. Weigh the risk of stroke and the severity of the bleeding. Consider additional factors, such as duration of the drug effects (one to two days in patients with normal renal function, but can be > 5 days with impaired renal function) and the onset of action when restarting (peak activity within two to four hours).

For severe or life-threatening bleeding
• Stop dabigatran
• Lab testing
  - CBC, platelet count, LFT, aPTT, INR, TT, creatinine and fibrinogen activity.
  - If TT is normal, no drug is present.
  - Repeat testing per institutional protocols or, at a minimum, every four to six hours until bleeding has stopped.
• Control the bleeding site and supportive care of patient
• Contact surgery or interventional radiology for embolization
• Administer activated charcoal if the drug has been given within two hours
• Consider dialysis, can remove 60% of the drug
  - Contact renal team
  - Place dialysis catheter under ultrasound guidance
• Blood transfusion
  - Transfuse RBCs per institutional guidelines or to keep Hgb > 8 gm/dL
  - After the 4th unit of RBCs, start giving RBCs and plasma on a 1:1 ratio (to avoid a dilutional coagulopathy)
- Cryoprecipitate, give 10 units after the 8th unit of RBCs, 4th unit of plasma – may not need cryoprecipitate if fibrinogen activity is > 100 mg/dL

- Recombinant activated factor VII or prothrombin complex concentrate could be considered if bleeding is life-threatening. They do not reverse the drug and the correct dose is unknown. Thrombosis is a potential side effect of both rFVIIa and PCC.

4.9a. Patient Education, Dabigatran

- Instruct patient to promptly report signs/symptoms of prolonged or excessive bleeding.
- Advise patient to notify physician or dentist of medication use prior to surgical procedures.
- Drug may cause unusual bruising, dyspepsia and gastritis-like symptoms.
- Tell patient not to discontinue the drug unless directed by a physician.
- Instruct patient to store drug in original bottle or blister package, not in any other container (e.g., pill boxes or organizers). Patient should open only one bottle at a time, remove only one capsule at the time of use, immediately close the bottle tightly after use, and date the bottle to expire 90 days after opening.
- Counsel patient to consult health care professional prior to new drug use (including over-the-counter and herbal drugs) as bleeding risk may increase with certain drugs (e.g., aspirin, NSAIDs).
- Instruct patient to take a missed dose as soon as possible, but if next dose is due in less than six hours, skip the missed dose. Patient should not take two doses at the same time.

4.0b. Key Considerations, Parenteral DTIs

Parenteral DTIs are presently approved for use in patients with active heparin-induced thrombocytopenia (HIT) and those with a previous history of HIT who require anticoagulation therapy.

Consultation with a hematologist or anticoagulation expert is recommended when using these new anticoagulant drugs because of both drug and disease complexities.

Argatroban

This is a small-molecular-weight reversible inhibitor of the active site of thrombin (univalent). This agent is excreted normally in patients with renal insufficiency, but the dose must be reduced in patients with hepatic impairment.

Bivalirudin

This is a semisynthetic bivalent inhibitor of thrombin. However, unlike hirudin, bivalirudin produces only transient reversal of thrombin and has a shorter half-life of 25 minutes. It has minimal renal excretion.

Lepirudin (recombinant hirudin)

Note that on April 1, 2012, lepirudin was removed from the European market. Lepirudin will no longer be manufactured after May 2013.

This is a potent specific inhibitor of thrombin that forms a slowly reversible complex with the enzyme by binding to both its active site and an exosite focus (bivalent effect). It is cleared predominantly by the kidneys with a half-life of 40 minutes post-IV dose and 120 minutes post-subcutaneous dose. It has almost irreversible binding to thrombin and has been associated with an increased risk of major bleeds in one study.
4.1b. Adverse Effects, Parenteral DTI

- Hemorrhage
- Patients with repeat courses of lepirudin may require more frequent monitoring due to antibody formation.

4.2b. Contraindications, Parenteral DTI

- Active major bleeding
- Hypersensitivity to hirudin, lepirudin, bivalirudin, argatroban

4.3b. Precautions, Parenteral DTI

- Severe hypertension
- History of recent major surgery
- History of recent major bleeding
- History of recent cerebrovascular accident
- Liver dysfunction (argatroban)
- Renal dysfunction (lepirudin) (lepirudin will no longer be manufactured after May 2013)
- Gastrointestinal ulceration
- Patients with repeat courses of lepirudin may require more frequent monitoring due to antibody formation.
- Rare case reports of anaphylaxis with re-exposure to lepirudin

4.4b. Pregnancy, Parenteral DTI

- FDA Pregnancy Category B (Micromedex) (Briggs, 2008 [R])

4.5b. Breastfeeding, Parenteral DTI

- Likely compatible, no human data (Briggs, 2008 [R])

4.6b. Dosing, Parenteral DTI

Testing should be obtained before initiation of direct thrombin inhibitors:

- Complete blood count (CBC)/Platelet count
- INR
- aPTT
- Liver enzymes (ALT, AST, GGT)
- Creatinine
Table 9. Treatment Options for HIT (with or without Thrombosis)

<table>
<thead>
<tr>
<th></th>
<th>Argatroban</th>
<th>Bivalirudin</th>
<th>Lepirudin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose adjustment necessary in patients with hepatic impairment.</strong></td>
<td>• Dose adjustment necessary in patients with renal impairment.</td>
<td>• No longer manufactured after May, 2013.</td>
<td></td>
</tr>
<tr>
<td><strong>Patients with heart failure, multiple organ system failure and anasarca, as well as those in the immediate post-cardiac surgery period, should receive an lower initial infusion rate (Warkentin, 2008a [R]).</strong></td>
<td>• Dose adjusted to maintain aPTT at 1.5-2.5 times normal.</td>
<td>• Dose adjustment necessary in patients with renal impairment.</td>
<td></td>
</tr>
<tr>
<td><strong>Dose adjusted to maintain aPTT at 1.5-3.0 times normal (not to exceed 100 seconds).</strong></td>
<td>• Dose adjusted to maintain aPTT at 1.5-2.5 times normal.</td>
<td>• There are two dosing regimens available the FDA-approved dose and an alternate dose recommended by the CHEST guidelines (Warkentin, 2008a [R]). The alternate dosing regimen has been recommended due to higher rates of bleeding associated with the FDA-approved dosing.</td>
<td></td>
</tr>
</tbody>
</table>
4.8b. Correction of Supratherapeutic Anticoagulation/Reversal, Parenteral DTI

The major side effect of DTIs is bleeding. There is no antidote for these medications should bleeding occur, which further supports the use of agents with a short half-life.

(Hirsh, 2004 [R]; Weitz, 2004 [R])

4.9b. Patient Education, Parenteral DTI

Importance of understanding aPTT and target ranges.

Know and watch for signs of bleeding.

5. Oral Direct Factor Xa Inhibitors

5.0. Key Considerations for Rivaroxaban

Rivaroxaban is an oral direct factor Xa inhibitor that selectively blocks the active site of factor Xa. Rivaroxaban does not require a cofactor (such as anti-thrombin) for activity.

Rivaroxaban 10 mg tablets may be taken without regard to food.

Based on pharmacokinetic data, food improves bioavailability of the 15 mg and 20 mg tablets; therefore, rivaroxaban 15 and 20 mg doses should be taken with food.

The maximum concentration of rivaroxaban occurs within two to four hours of administration. The terminal elimination half-life of rivaroxaban is five to nine hours in healthy subjects.

- Rivaroxaban is FDA approved for prevention of DVT and PE in patients undergoing knee or hip replacement surgery, treatment of DVT and PE reduction in the risk of recurrence of DVT and PE and for non-valvular atrial fibrillation for stroke prevention.
- Like warfarin and dabigatran, it requires the same careful risk/benefit assessment for patients at great risk for hemorrhage.
- Avoid use of rivaroxaban for treatment of DVT and PT, reduction of risk of recurrence of DVT and PE and prevention of DVT and PE in patients undergoing knee or hip replacement surgery with a creatinine clearance (CrCl) < 30 mL/min.
- Avoid use of rivaroxaban in patients with non-valvular atrial fibrillation and a creatinine clearance (CrCl) < 15 mL/min.
- Prior to procedures, the rivaroxaban must be held at least 24 hours. Longer times may be considered for patients with renal impairment, having major surgery and/or spinal puncture.
- An increased rate of stroke has been observed during transition from rivaroxaban to warfarin in patients with non-valvular atrial fibrillation. If rivaroxaban must be stopped for a reason other than bleeding, consider administering another anticoagulant.
- No antidote is available.

5.1. Adverse Effects, Rivaroxaban

Most common adverse reactions with rivaroxaban are bleeding complications.

In a pooled analysis of eight randomized controlled trials (including the RECORD Programme: RECORD 1, 2, 3 and 4), which involved 15,586 patients comparing enoxaparin and rivaroxaban thromboprophylaxis...
in hip or knee arthroplasty, there was no significant difference in the incidence of bleeding events between enoxaparin and rivaroxaban (RR 1.65, 95% CI 0.93-2.93) (Cao, 2010 [M]).

The table below shows the number of patients in the ROCKET AF trial experiencing various types of bleeding.

**Table 10.**

<table>
<thead>
<tr>
<th></th>
<th>Rivaroxaban N (%)</th>
<th>Warfarin N/</th>
<th>HR, 95% CI, p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/100 patient years</td>
<td>n/100 patient years</td>
<td></td>
</tr>
<tr>
<td>Major and non-major clinically relevant bleeding* (principal safety endpoint)</td>
<td>1475 (20.7%)</td>
<td>14.9</td>
<td>1449 (20.3%)</td>
</tr>
<tr>
<td>Fatal bleeding</td>
<td>27 (0.4%)</td>
<td>0.2</td>
<td>55 (0.8%)</td>
</tr>
<tr>
<td>Intracranial hemorrhage</td>
<td>55 (0.8%)</td>
<td>0.5</td>
<td>84 (1.2)</td>
</tr>
<tr>
<td>Non-major clinically relevant bleeding</td>
<td>1185 (16.7%)</td>
<td>11.8</td>
<td>1151 (16.2%)</td>
</tr>
</tbody>
</table>

*Minimal bleeding events were not included in principal safety endpoint. (Patel, 2011 [A])

5.2. Contraindications, Rivaroxaban

Patients with prohibitive bleed risks were not included in studies of rivaroxaban. As with all anticoagulants, extreme caution should be used in giving rivaroxaban to patients with bleeding diatheses, fall risks, alcohol abuse or compliance issues. An individual patient's risk of thrombosis versus risk of bleeding needs to be assessed before use of this or any anticoagulant.

Pregnant patients and those with valvular heart disease have not been studied and are not candidates for this drug.

Dose adjustment or avoidance of rivaroxaban should be considered in patients with severe renal insufficiency, especially if the patient's kidney function is in flux.

Moderate (Child-Pugh B) and severe hepatic (Child-Pugh C) impairment or with any hepatic disease associated with coagulopathy.

5.3. Precautions, Rivaroxaban

An increased rate of stroke was observed in the ROCKET AF trial during transition from rivaroxaban to warfarin in patients with non-valvular atrial fibrillation. If rivaroxaban must be stopped for a reason other than bleeding, consider administering another anticoagulant (Patel, 2011 [A]).

**Drug Interactions**

**Drug-drug interactions**

Rivaroxaban is a substrate of CYP3A4/5 and p-glycoprotein (P-gp). Inhibitors and inducers of these CYP450 enzymes or transporter may result in changes in rivaroxaban exposures.
Drugs that are combined P-gp and CYP3A4 inhibitors increase rivaroxaban concentration (e.g., ketoconazole, ritonavir, clarithromycin, erythromycin, fluconazole). It is recommended to avoid concomitant administration of rivaroxaban with combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin).

Drugs that are combined P-gp and strong CYP3A4 inducers decrease rivaroxaban concentration. It is recommended to avoid concomitant administration of rivaroxaban with P-gp and strong CYP3A4 inducers (e.g., rifampin).

Use of other anticoagulants, antiplatelets, NSAIDs or aspirin increase the risk of bleeding. Aspirin monotherapy (less than 100 mg) and thienopyridine monotherapy were allowed in ROCKET AF trial. Only 34.9% of rivaroxaban patients took aspirin (less than 100 mg) sometime during trial. Thienopyridine use was not reported in the trial (Patel, 2011 [A]).

**Drug-disease interactions**

Patients with renal impairment receiving full dose rivaroxaban concomitantly with drugs that are combined P-gp and weak or moderate CYP3A4 inhibitors (e.g., amiodarone, azithromycin, diltiazem, dronedarone, verapamil) may have significant increases in rivaroxaban concentration.

5.4. Pregnancy, Rivaroxaban

Pregnancy category C. There are no adequate or well-controlled studies of rivaroxaban in pregnant women, and dosing for pregnant women has not been established.

Pregnant patients are not candidates for this drug.

5.5. Breastfeeding, Rivaroxaban

It is not known if rivaroxaban is excreted in human milk. Rivaroxaban and/or its metabolites were excreted in the milk of rats. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from rivaroxaban, a decision should be made whether to discontinue nursing or discontinue rivaroxaban, taking into account the importance of the drug to the mother.

5.6 Dosing, Rivaroxaban

**DVT/PE prophylaxis in hip/knee replacement efficacy data**

In a pooled analysis of eight randomized controlled trials (including the RECORD Programme: RECORD 1, 2, 3 and 4), which involved 15,586 patients comparing enoxaparin and rivaroxaban thromboprophylaxis in hip or knee arthroplasty, rivaroxaban was found to be associated with significantly fewer VTE events and all-cause mortality when compared to enoxaparin (RR 0.56, 95% CI 0.39-0.80) (Cao, 2010 [M]).

**DVT/PE prophylaxis in hip/knee replacement dosing**

The FDA-approved dosing of rivaroxaban for prevention of DVT/PE in patients undergoing hip or knee replacement is 10 mg once daily with or without food. Avoid use in patients with a creatinine clearance (CrCl) < 30 mL/min. The initial dose should be taken at least 6-10 hours after surgery once hemostasis has occurred.

For patients undergoing:
- Hip replacement: treatment duration of 35 days is recommended
- Knee replacement: treatment duration of 12 days is recommended
Institute for Clinical Systems Improvement

DVT and PE treatment and reduction in the risk of recurrence of DVT and PE dosing

The FDA approved dose is 15 mg twice a day for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, the dose is 20 mg once daily for the rest of the treatment period for the long-term reduction in the risk of recurrence of DVT or PE. Avoid use in patients with a creatinine clearance (CrCl) < 30 mL/min.

Non-valvular atrial fibrillation efficacy data

A multicenter, randomized, double-blind, double-dummy, event-driven, non-inferiority trial included 14,264 patients with non-valvular atrial fibrillation, median age 73 years old, and a mean CHADs score of 3.4. Patients were randomized to rivaroxaban 20 mg once daily or 15 mg once daily in patients with a CrCl between 30-49 mL/min or dose-adjusted warfarin once daily. Primary endpoint was stroke or systemic embolism. The Rosendaal method was used to calculate time the INR was within therapeutic range: mean 55%, median 58% (interquartile range, 43-71%). Median follow-up period was 707 days (Patel, 2011 [A]).

Table 11. Efficacy Results

<table>
<thead>
<tr>
<th></th>
<th>Rivaroxaban</th>
<th>Warfarin</th>
<th>HR, 95% CI, p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Per protocol as treated population (n=6,958)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke or systemic embolism</td>
<td>1.7%/year (n=188)</td>
<td>2.2%/year (n=241)</td>
<td>HR=0.79, 95% CI, 0.66-0.96, P&lt;0.001</td>
</tr>
<tr>
<td>Intention-to-treat population (non-inferiority and superiority) (n=7,081)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke or systemic embolism</td>
<td>2.1%/year (n=269)</td>
<td>2.4%/year (n=306)</td>
<td>HR=0.88, 95% CI, 0.74-1.03, Non-inferiority: p&lt;0.001, Superiority: p=0.12</td>
</tr>
</tbody>
</table>

(Patel, 2011 [A])

Non-valvular atrial fibrillation dosing

The FDA-approved dosing of rivaroxaban for use in non-valvular atrial fibrillation is 20 mg once daily with evening meals for patients with CrCl > 50 mL/min. For patients with CrCl 15-50 mL/min, the recommended dose is 15 mg once daily with evening meals. Avoid use in patients with a CrCl < 15 mL/min.

Perioperative management

If rivaroxaban must be discontinued to reduce the risk of bleeding for any type of procedure, rivaroxaban should be stopped at least 24 hours prior to the procedure. Longer times may be considered for patients with renal impairment, having major surgery and/or spinal puncture.

Rivaroxaban should be restarted after the procedure as soon as adequate hemostasis has been achieved.

5.7. Monitoring and Effect on Laboratory Testing, Rivaroxaban

Routine monitoring of rivaroxaban is not needed. In some clinical situations, evaluation of rivaroxaban effect would be helpful. These situations include rivaroxaban-treated patients presenting with thrombosis or hemorrhage, possible overdose, evaluation of compliance and assessment of rivaroxaban effect prior to surgery. A chromogenic Xa assay using rivaroxaban calibrators and controls would be helpful in this assessment; however, this assay is not yet available in the routine coagulation laboratory (Lindhoff-Last, 2010 [C]).

Rivaroxaban prolongs the prothrombin time (PT) as well as the activated partial thromboplastin time (aPTT) at near peak levels two hours after drug administration. This prolongation is not seen 12 hours after the
dose is given. The degree of prolongation is dependent on the reagents used for the assays. The thrombin time (TT) is not affected by rivaroxaban. Fibrinogen levels using the Clauss method are not affected by rivaroxaban. However, fibrinogen measurements using an assay derived from the PT assay are prolonged two hours after drug administration. This prolongation is variable and dependent on the reagents used for the test (Mani, 2011 [C]).

NOTE: Consensus-based statements comprise the content of this section on rivaroxaban. It is important to note that, at the time of writing, there was little data to support these consensus-based recommendations.

There are limited options for management of bleeding on rivaroxaban as there is no antidote for reversal of the anticoagulation effect of the drug.

If rivaroxaban was consumed within two hours of presentation, activated charcoal, at standard doses, should be considered.

Rivaroxaban is highly protein bound and is not expected to be dialyzable.

Fresh frozen plasma infusion will not reverse the anticoagulation effect of rivaroxaban, as the drug will inhibit factor X in the transfused plasma. (It is important to note that the prolonged clotting times on rivaroxaban are a reflection of factor X inhibition and not a clotting factor deficiency.)

As a last resort, one could consider use of procoagulant hemostatic agents such as recombinant factor VIIa (rFVIIa) activated or non-activated prothrombin complex concentrates (PCC). In healthy subjects, the anticoagulant effect of rivaroxaban could be reversed with administration of a non-activated PCC (Erenberg 2011 [A]).

The ICSI work group has included recombinant activated factor VII (rFVIIa) or prothrombin complex concentrate as options to help with clot formation at the site of bleeding. They do not reverse the drug, the correct dose is unknown, and there is no FDA approval for this use. Thrombosis is a known side effect of rFVIIa and PCC.

Protocol for management of bleeding on rivaroxaban

Consensus-Based Protocol for Bleeding Management

NOTE:

- Primary use would be in the emergency room and hospital settings where adult patients on rivaroxaban are bleeding.
- Consensus-based statements comprise the content of this section on rivaroxaban. It is important to note that, at the time of writing, there was little data to support these consensus-based recommendations.
- There is no specific agent to reverse the drug.
- Plasma will not reverse the drug as rivaroxaban will inhibit factor X in transfused plasma.
- There is very little data to help guide us in managing bleeding complications on the drug.

**NOTE**

- The PTT and INR may be abnormal on rivaroxaban.
- Clotting times do not accurately reflect drug levels.
For minor bleeding

- Evaluate drug compliance, change in renal function, whether anatomical defects explain hemorrhage.
- Use local measures to control the bleeding.
- Keep hydrated.
- Replace fluids and blood products as needed.
- Clinical judgment to hold or continue rivaroxaban. Stopping the drug will decrease the bleeding risk, but may increase risk of stroke. Weigh the risk of stroke and the severity of the bleeding. Consider additional factors, such as duration of the drug effects and the onset of action when restarting (peak activity within two to four hours).

For severe or life-threatening bleeding

- Stop rivaroxaban
- Lab testing
  - CBC, platelet count, LFT, aPTT, INR, TT, creatinine and fibrinogen activity.
  - Repeat testing per institutional protocols or, at a minimum, every four to six hours until bleeding has stopped
- Control the bleeding site and supportive care of patient
- Contact surgery or interventional radiology for embolization
- Administer activated charcoal if the drug has been given within two hours.
- Blood transfusion
  - Transfuse RBCs per institutional guidelines or to keep Hgb > 8 gm/dL.
  - After the fourth unit of RBCs, start giving RBCs and plasma on a 1:1 ratio (to avoid a dilutional coagulopathy).
  - Cryoprecipitate, give 10 units after the eighth unit of RBCs, fourth unit of plasma – may not need cryoprecipitate if fibrinogen activity is > 100 mg/dL.
- Recombinant activated factor VII or prothrombin complex concentrate could be considered if bleeding is life-threatening. They do not reverse the drug and the correct dose is unknown. Thrombosis is a potential side effect of both rFVIIa and PCC.

5.9. Patient Education, Rivaroxaban

- Instruct patient to promptly report signs/symptoms of prolonged or excessive bleeding.
- Advise patient to notify physician or dentist of medication use prior to surgical procedures.
- Tell patient not to discontinue the drug unless directed by a physician.
- Advise patient that there are multiple significant drug-drug interactions for this drug and to consult health care professional prior to any new drug use (including over-the-counter and herbal drugs) as bleeding risk may increase with certain drugs (e.g., aspirin, NSAIDs, St. John's wort).
6. Antiplatelet Agents

6.0. Introduction, Antiplatelet Agents

Platelet involvement with pathologic thrombosis and vascular occlusion in both venous and arterial systems has been a recognized target and challenge for therapeutic intervention. Antiplatelet drugs provide relatively safe and variably efficacious alternatives for reduction of excessive risk in several common clinical conditions, notably cardiac and cerebral atherothrombosis. In modern clinical practice, antiplatelet drugs play a role with other means of risk reduction in both primary and secondary prevention of vascular morbidity, and in selected acute event-management situations. There is substantial basic scientific and clinical trial data available to make rational and selective management decisions for individual patients in all conceivable settings of clinical practice.

Principles:

1. Antithrombotic therapeutic benefit is relative to individual patient morbidity, tolerance and hemorrhagic risk.
2. In general, individual patient thrombotic risk must exceed 3% per year to realize a clinically meaningful benefit from antiplatelet drugs.

6.0a Key Considerations for Oral Antiplatelet Agents

- **Aspirin**

  Thoroughly evaluated for over 30 years as an antiplatelet drug, aspirin has been confidently determined to prevent vascular death by 15%, and to prevent non-fatal vascular events by about 30%, based on meta-analysis of over 100 randomized trials (Antithrombotic Trialists, 2002 [M]). The whole spectrum of atherosclerosis has been evaluated, from low-risk, apparently healthy individuals to those with acute stroke and myocardial infarction, with observation intervals from a few weeks to several years. Both absolute benefits and the size of proportional effects are heterogeneous in different clinical settings.

  Its antithrombotic effect derives from the permanent inactivation of cyclooxygenase-1, or COX-1, expressed in megakaryocytes and platelets. This enzyme begins prostanoid biosynthesis, resulting in several prostaglandins, including particularly thromboxane-A2, which activates platelets with adhesion to (damaged) vascular intima and release of other cytokines, resulting in local thrombus formation. Since only 10% of the platelet pool is replenished each day, once-daily dosing is adequate to maintain virtually complete inhibition of prostaglandin-mediated activation of platelet thrombogenic processes.

  Its somewhat dissimilar effect on the isomer COX-2, expressed in many tissues but particularly monocytes, constitutes its anti-inflammatory benefits. There is an approximately 100-fold greater dose requirement for anti-inflammatory as for antithrombotic effects of aspirin.

  Aspirin is rapidly absorbed in the stomach and upper intestine, and inhibition of platelet function is evident within one hour. This process is significantly slowed by enteric coating of tablets.

- **Thienopyridines (clopidogrel, prasugrel)**

  Thienopyridines selectively block the ADP receptor PP2Y12, thus preventing ADP-induced platelet aggregation. Both clopidogrel and prasugrel are orally administered inactive prodrugs; after absorption, they are converted to their active metabolites by liver cytochrome (CYP) P450 complex of enzymes. Clopidogrel is converted by the CYP 2C19 and prasugrel by the CYP 3A4 and 2B6 enzymes. Conversion of clopidogrel by the CYP2C19 enzyme is dependent on the genotype of that enzyme.
Recovery of platelet function after drug discontinuation requires about seven days, paralleling the
dynamic of platelet turnover, suggesting that as with aspirin, the active CPG metabolite permanently
affects platelet protein, which cannot be repaired within the platelet lifespan.

- **Cyclopentyltriazolopyrimidine (ticagrelor)**

  With generic clopidogrel availability, it is likely clopidogrel will remain the mainstay of therapy in
patients with acute coronary syndrome and newer agents will be used for patients at high risk for
developing stent thrombosis.

**Drug interaction with proton pump inhibitors (PPI)**

Proton pump inhibitors (PPIs), typically used in conjunction with antiplatelet agents such as clopidogrel to
reduce gastrointestinal blood loss, result in reduced plasma concentrations of active metabolite of clopidogrel,
thus lowering the antiplatelet effect of clopidogrel in vitro *(Gilard, 2008 [A])* . This interaction is due to
competitive inhibition of the metabolism of clopidogrel by CYP2C19, which generates its active metabolite.

In November 2009 the FDA issued a statement advising prescribers that in patients taking clopidogrel, to
avoid using selected PPIs (and other drugs – e.g., cimetidine, esomeprazole, fluoxetine, fluconazole, keto-
conazole) that inhibit CYP2C19.

(http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/Drug-
SafetyInformationforHealthcareProfessionals/ucm190787.htm last accessed February 1, 2011)

Though the FDA issued a boxed warning, post-hoc analysis of two studies *(Ray, 2010 [B]; O'Donoghue, 2009
[A])* does not confirm these adverse cardiovascular outcomes. It has been difficult for clinicians to assimilate
this information and to develop strategies for managing patients who might benefit from antiplatelet therapy,
yet who might suffer from GI bleeding. In 2010, the American College of Cardiology Foundation (ACCF),
the American College of Gastroenterology (ACG), and the American Heart Association (AHA) issued an
expert consensus document on the concomitant use of proton pump inhibitors (PPI) and thienopyridines.

The gastroprotective effects of PPIs were demonstrated in results from COGENT trial *(Bhatt, 2010 [A])* . In
patients requiring dual antiplatelet therapy (clopidogrel and aspirin), the incidence of gastrointestinal (GI)
hemorrhage in patients on omeprazole (1.1%) was reduced compared to patients on placebo (2.9% HR 0.34,
95% CI, 0.18 to 0.63; P<0.001). Although the rate of cardiovascular events in patients on omeprazole was
not increased, this study was not powered to detect such a difference.

- Risks and benefits of concomitant clopidogrel and PPI use must be carefully evaluated and docu-
mented on an individual patient basis.
- Patients with recent history of GI bleeding are at highest risk for recurrent bleeding on antiplatelet
therapy.
- Use of PPI or a H2 blocker reduces the risk of upper GI bleeding compared with no therapy (PPI
reduce the risk more than H2 blockers).
- PPIs are recommended to reduce GI bleeding among patients with a history of upper GI bleeding.
PPIs are appropriate in patients with multiple risk factors for GI bleeding who require antiplatelet
therapy.
- Routine use of either PPI or an H2 blocker is not recommended for patients at low-risk of upper GI
bleeding.
- Discontinue PPI if there is no indication.

*(Abraham, 2010 [R])*
CYP2C19 gene polymorphisms and clopidogrel effect

Polymorphisms (or variants or different alleles) of the CYP2C19 enzyme have been shown to affect metabolism of clopidogrel. Patients who have two normal metabolism alleles (also termed wild type, or CYP2C19*1) have fully functional normal metabolism. Patients with one or two loss-of-function allele have a reduced metabolism of clopidogrel.

These patients with reduced clopidogrel metabolism show suboptimal platelet inhibition that may result in increased cardiovascular morbidity and mortality compared to normal metabolizers. However, there are multiple non-genetic and genetic variables that affect platelet inhibition.

In March 2010 the FDA issued a new boxed warning to the product label of clopidogrel bisulfate (marketed as Plavix). The exact wording of the black box warning is as follows:

The effectiveness of clopidogrel hydrogen sulfate is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19. Clopidogrel hydrogen sulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers. Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel hydrogen sulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy. Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.

Specifically, the purpose is to:

- warn about reduced effectiveness in patients who are poor metabolizers of clopidogrel – poor metabolizers do not effectively convert clopidogrel to its active form in the body; decreased responsiveness has been associated with worse outcomes in clinical trials;
- inform health care professionals that tests are available to identify genetic differences in CYP2C19 function, and platelet function testing; and
- advise health care professionals to consider use of other anti-platelet medications or alternative dosing strategies for clopidogrel in patients identified as poor metabolizers.


In response to the FDA warnings, the American College of Cardiology Foundation task force and American Heart Association have issued a joint statement pointing to the lack of definitive data to guide endorsement of a specific treatment strategy, noting that clinical trials are currently under way to help address the matter.

Another summary from ACCF/AHA issued in June of 2010 re-emphasized the above findings, and stated that the clinical outcomes of specific genetic polymorphisms is undetermined and the predictive value of pharmacogenomics and platelet function testing is unknown.

There is insufficient information to recommend either routine genetic or platelet function testing at this time, and there is no randomized data to suggest testing improves outcomes. Clinical judgment should be used to assess clinical risk, and genetic testing may be considered in individuals thought to be high risk.

Pending availability of evidence-based guidelines, practical patient management suggestions have been made (Holmes, 2010 [R]).

Key messages from this statement include:

- Residual platelet reactivity in patients receiving clopidogrel is associated with increased risk of cardiac and cerebrovascular and peripheral arterial events.
• This variability, due to pharmacokinetic and pharmacodynamic factors, is due to multiple factors including variables such as increased age, body mass index, comorbidities such as diabetes and dyslipidemia. Genetic variability likely explains only a small proportion of this variation.

• Genetic testing for CYP2C19 (pharmacogenetic testing) is not widely available; in addition, generally test turnaround times preclude applicability of the information for acute phases of patient care.

• Point-of-care testing for the CYP2C19 is not yet available.

• Costs of these tests are typically high and not reimbursed by major payers.

In spite of limitations in available data, some practical recommendations for practice were provided:

• Adherence to the existing ACCF/AHA guidelines for use and a platelet therapy should remain the foundation for practice.

• The predicted value of pharmacogenetic testing is limited and is a focus of multiple ongoing clinical studies.

• The evidence for routine pharmacogenetic testing is insufficient; however, in patients felt to be at moderate or high risk for poor outcomes (patients undergoing elective high-risk PCI procedures or treatment of extensive or complex disease), pharmacogenetic testing may be considered with alternative therapy (e.g., prasugrel) in patients predicted to be poor metabolizers.

• For patients experiencing recurrent thrombosis despite clopidogrel, options include increasing the dose of clopidogrel or consideration of alternatives such as prasugrel.

6.1a. Adverse Effects, Oral Antiplatelet Agents

Combination of aspirin and clopidogrel and/or combination with warfarin or other anticoagulant has been shown to increase the risk of major bleeding.

Aspirin

Hemorrhage, with underlying hemostatic defects: uremia, hemophilia, anticoagulation therapy. Hemorrhage, without defects: OR 1.6 in high-risk patients (Antithrombotic Trialists, 2002 [M]).

Gastric irritation: dose-related (Chan, 2005 [A]; Dutch TIA Trial, 1991 [A])

• No better with coated or buffered tablets (Kelly, 1996 [D])

• Influence of concomitant COX-2 inhibitors/NSAIDs

• Withhold NSAIDs for 30 minutes after taking aspirin

Thienopyridines (clopidogrel, prasugrel)

Thrombotic thrombocytopenic purpura (TTP), sometimes life-threatening, may occur, usually within two weeks of treatment initiation (Bennett, 2000 [D]).

Hemorrhage 9%; severe in 1-2%/year of chronic treatment

Thrombocytopenia

Allergic rash

Diarrhea
6.2a. Contraindications, Oral Antiplatelet Agents

- Major hemorrhage
- Hypersensitivity to NSAIDs (aspirin)
- Platelet count less than 50,000

6.3a. Precautions, Oral Antiplatelet Agents

- Patients at risk of increased bleeding from trauma, surgery or other pathological condition (particularly gastrointestinal and intraocular)
- Alcohol use (three or more drinks/day)
- Pregnancy (third trimester)
- Gastrointestinal symptoms, peptic ulcer disease
- Renal failure
- Severe hepatic insufficiency
- Concomitant use of more than one antithrombotic drug
- Syndrome of asthma, rhinitis and nasal polyps

6.4a. Pregnancy, Oral Antiplatelet Agents

Third-trimester risks of placental separation and hemorrhage (Caritis, 1998 [A]). FDA class D positive evidence of human fetal risk. Maternal benefit may outweigh fetal risk in serious or life-threatening situations.

6.5a. Breastfeeding, Oral Antiplatelet Agents

FDA class Possibly Unsafe: Available animal or human data demonstrates potential or actual adverse effects to infants. Consider alternatives or weigh risks and benefits. Some community practice reflects use of 81 mg ASA daily as antiplatelet therapy.

6.6a. Dosing, Oral Antiplatelet Agents

**Aspirin**

For all clinically important endpoint events, oral doses ranging between 81 and 325 mg/day are sufficient. Higher doses thought in the past to be required for clinical effects have been shown to be unnecessary and are undesirable because of dose-related gastric and hemorrhagic side effects.

Aspirin therapy at a dose of 50 to 100 mg is recommended for patients with cryptogenic stroke and a patent foramen ovale or atrial septal aneurysm. No aspirin therapy is recommended for asymptomatic patent foramen ovale or atrial septal aneurysm.
Aspirin Resistance
Some patients at risk, as well as volunteer subjects, have shown variably submaximal responses to aspirin, as assessed by bleeding time and \textit{in vitro} laboratory evaluations of platelet response to ADP (adenosine diphosphate) and other activating agents. Methodologic and statistical issues of sampling, and the functional limitations of available laboratory tests, are likely explanations for the failure to observe such variable dosing requirements in clinical trials.

The ultimate evidence of aspirin resistance would be occurrence of thrombosis and treatment failure, although the presumption of resistance is confounded by the many other factors promoting thrombogenesis at local tissue sites.

\textbf{Dipyridamole/aspirin}

Antiplatelet oral dose containing 200 mg modified-release dipyridamole plus 25 mg aspirin. Standard-release oral dipyridamole is considered to be unreliable due to erratic absorption (Derendorf, 2005 [A]).

Clopidogrel loading dose of 300-600 mg (Von Beckerath, 2005 [A]; Savcic, 1999 [A]) results in more rapid effectiveness, but no scientifically established ideal loading schedule is available. A patient-selective phenomenon of "resistance" has been observed, as with ASA, but again no reliable laboratory test of anti-platelet effect can be recommended.

\textbf{Prasugrel}

Prasugrel is FDA approved for acute coronary syndrome in patients undergoing percutaneous coronary intervention (PCI). The recommended loading dose is 60 mg x1, followed by a maintenance dose of 10 mg once daily. Patients should also take concomitant aspirin 75-325 mg once daily.

Prasugrel and clopidogrel were compared head to head in the TRITON-TIMI 38 trial. This trial included 13,608 patients with moderate- to high-risk acute coronary syndrome with scheduled PCI. Patients were randomized to receive prasugrel (60 mg loading dose and 10 mg once-daily maintenance dose) or clopidogrel (300 mg loading dose and 75 mg once-daily maintenance dose) for 6-15 months. The primary endpoint was death from cardiovascular causes, non-fatal myocardial infarction (MI) or non-fatal stroke. The primary safety endpoint was bleeding. Prasugrel was found to be more effective than clopidogrel at reducing the primary endpoint (12.1% vs 9.9%, HR, 0.81; 95% CI 0.73-0.90; p<0.001). However, prasugrel had a greater incidence of life-threatening bleeding (1.4% vs 0.9%, HR, 1.32; 95% CI 1.03-1.68; p=0.03) (Wiviott, 2007 [A]).

Prasugrel has a FDA black box warning regarding bleeding risk, and patient selection is important.

Candidates for prasugrel should meet the following criteria:

- Acute coronary syndrome managed by PCI
- Receiving adjunct aspirin therapy
- Not undergoing CABG
- < 75 years old
- Weight \geq 60 kg
- No history of TIA/stroke or bleeding predisposition (Wiviott, 2007 [A])

Clinical studies of combined use of clopidogrel and aspirin have shown mixed results. In patients in the CURE Study with acute coronary syndromes, addition of ASA 75-325 mg to clopidogrel 75 mg resulted in reduced occurrence of the compound endpoints MI, stroke and vascular death, but with severe hemorrhagic events increased by combination therapy, and related to dose of ASA. The increased bleeding was
considered to be acceptable given the benefits attained. In this clinical setting, the ASA dose should be 81 mg (Peters, 2003 [A]).

Two studies of combined use in secondary stroke prevention concluded that there was no benefit for the same compound endpoints, and the combination consequently discouraged due to increased hemorrhagic risk. The MATCH study found 3% major hemorrhage with combined clopidogrel 75 mg and ASA 75 mg, nearly identical to that in CURE (Diener, 2004 [A]). The CHARISMA study of clopidogrel 75 mg and ASA 75-162 mg had only 1.7% combined therapy bleeding (versus ASA alone), but still unacceptable in the absence of benefit (Bhatt, 2006 [A]).

**Ticagrelor**

Ticagrelor is a P2Y12 platelet inhibitor with the FDA indication to reduce the rate of thrombotic cardiovascular events in patients with ACS (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). In the PLATO Trial (Connolly, 2009 [A]), ticagrelor reduced the combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. Ticagrelor's benefit over clopidogrel was driven by cardiovascular (CV) death and MI with no difference in stroke.

Dosage and Administration: Initiate treatment with 180 mg (two 90 mg tablets) and continue with 90 mg twice-a-day maintenance dose. After the initial loading dose of aspirin of 325 mg, use a daily maintenance dose of 75-100 mg, as doses greater than 100 mg reduce the effectiveness of ticagrelor. Patients who have received a loading dose of clopidogrel can be started on ticagrelor. A patient who misses a dose of ticagrelor should take one 90 mg tablet (his/her next dose) at its scheduled time.

FDA issued a black box warning for ticagrelor regarding bleeding risk, and patient selection is important. Contraindications include history of intracranial hemorrhage, active pathological bleeding, or severe hepatic impairment, since the latter increases the risk of bleeding because of reduced synthesis of coagulation proteins. Caution should be used in patients with a gastrointestinal bleed within the past six months.

Drug Interactions: Ticagrelor is predominantly metabolized by CYP3A4 and to a lesser extent by CYP3A5. Avoid use with strong CYP3A inhibitors, such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole, which increase ticagrelor blood levels. Also avoid use with potent CYP3A inducers (rifampin, dexamethasone, phenytoin, carbamazepine, and phenobarbital), which substantially reduce ticagrelor blood levels and should be avoided. Doses of simvastatin and lovastatin greater than 40 mg should be avoided since ticagrelor will result in higher serum concentrations of these drugs which are metabolized by CYP3A4. Because of inhibition of the P-glycoprotein transporter, digoxin levels should be monitored with initiation of or any change in ticagrelor therapy. When possible, discontinue ticagrelor at least five days prior to any surgery.

Dyspnea was reported in 14% of patients treated with ticagrelor and in 8% of patients taking clopidogrel in the PLATO Trial. If a patient develops new, prolonged or worsened dyspnea during treatment with ticagrelor, exclude underlying diseases that may require treatment. If dyspnea is determined to be related to ticagrelor, no specific treatment is required; the drug should be continued without interruption. Dyspnea is usually mild to moderate in intensity, often resolves during continued treatment and is self-limiting.

**Combination Antiplatelet Therapy**

Combined antiplatelet therapy has been used in acute coronary syndrome for some time and proven to be effective (Yusuf, 2001 [A]).

Two clinical studies have addressed the effectiveness of combined aspirin with clopidogrel for prevention of stroke in atrial fibrillation (Connolly, 2009 [A]; ACTIVE Writing Group, The, 2006 [A]). ACTIVE A compared aspirin with combined aspirin and clopidogrel in patients who were considered to be poor candidates for warfarin therapy. This showed that the combination reduced incidence of both stroke (2.4 vs. 3.3%) and myocardial infarction (0.2% vs. 0.9%), but increased risk of major hemorrhage from 1.3 to
2.0% per year, compared to aspirin alone. In the ACTIVE W study, warfarin was significantly better than combined ASA/clopidogrel therapy in the prevention of embolic stroke.

In patients with atrial fibrillation, providers should carefully select use of warfarin versus aspirin (with or without clopidogrel), based on the relative risk of stroke versus the overall risk of hemorrhage using these therapies (Connolly, 2009 [A]; ACTIVE Writing Group, The, 2006 [A]).

**Perioperative Management of Antiplatelet Agents**

Patients receiving antiplatelet agents should have these agents stopped 2-10 days prior to a procedure:
- Clopidogrel and prasugrel seven days prior to surgery
- Aspirin 7-10 days prior to surgery
- Ibuprofen two days prior to surgery

Patients with recent coronary stenting may have significant risk of stent thrombosis if antiplatelet therapy is interrupted. Consultation with a cardiologist is recommended to determine the best course of action in these patients (Jaffer, 2009 [R]).

---

**6.7a. Monitoring, Oral Antiplatelet Agents**

In most clinical situations, monitoring of oral antiplatelet agents is not required. There are no laboratory methods that have been shown effective in monitoring antiplatelet activity in patients. In patients where the risk of bleeding is a concern, monitoring may include CBC/platelet count.

---

**6.8a. Correction of Supratherapeutic Anticoagulation/Reversal, Oral Antiplatelet Agents**

Platelet infusion if bleeding.

---

**6.9a. Patient Education, Oral Antiplatelet Agents**

Importance of understanding antiplatelet agents and target ranges.

Know and watch for signs of bleeding.

Restrictions for other conditions including deep vein thrombosis, stroke or coronary artery disease. Please refer to related ICSI guidelines for more information.

Importance to adhering to prescribed regimen.

---

**6.0b. Key Considerations for Parenteral Antiplatelet Agents**

- **Platelet glycoprotein IIb/IIIa antagonists**

  Activation of the platelet surface receptor – P2Y12/Integrin – is the final common pathway for many metabolic activators of platelet aggregation. Agents blocking this activation include naturally occurring polypeptides (snake venoms), synthetic polypeptides and monoclonal antibodies. In addition, these agents also inhibit thrombin generation, which is likely of importance. There are interactions with ASA, clopidogrel, heparins and thrombolytics.
6.1b. Adverse Effects, Parenteral Antiplatelet Agents

Major bleeding

Thrombocytopenia (less than 5,000/microliter) less than 1-2%, usually asymptomatic (Labinaz, 2007 [M])

6.2b. Contraindications, Parenteral Antiplatelet Agents

- Bleeding diathesis or oral anticoagulant use within seven days
- History of vasculitis
- Intracranial tumor, arteriovenous malformation or aneurysm
- Major surgery or trauma
- Severe uncontrolled hypertension
- Thrombocytopenia
- Active or recent internal bleeding

6.3b. Precautions, Parenteral Antiplatelet Agents

- Concomitant administration with thrombolytics, oral anticoagulants, NSAIDs, dipyridamole and other antiplatelet drugs increase the risk of bleeding.
- A low-dose, weight-adjusted heparin regimen is recommended to minimize the risk of bleeding.
- Minimize arterial and venous punctures, IM injections and use of urinary catheters, nasotracheal intubation, nasogastric tubes and automatic blood pressure cuffs.
- Arterial sheath should not be removed unless aPTT is 50 seconds or less, OR the activated clotting time is 175 seconds or less, and heparin has been discontinued for at least two hours.
- Full-dose heparin should be stopped at least two hours before femoral artery sheath removal and adequate hemostasis are achieved.
- Patients should be maintained on adequate bed rest following sheath removal or discontinuation of IIB/IIIA inhibitors.
- Thrombocytopenia has been observed; platelet counts should be monitored.

6.4b. Pregnancy, Parenteral Antiplatelet Agents

Little information is known, and not all platelet glycoprotein antagonist drugs have been studied. All studies to date have been animal studies.

6.5b. Breastfeeding, Parenteral Antiplatelet Agents

Little information is known, but it does not appear that parenteral antiplatelet drugs are excreted in breast milk.
6.6b. Dosing, Parenteral Antiplatelet Agents

**Abciximab**
IV bolus 0.25 mg/kg plus 0.125 microgm/kg/min infusion; effective in 80% or more in PCI subjects
Half-life at 30 minutes; 65% attachment to platelet surface
Peak effects at 2 hours: receptor blockade, aggregation, bleeding time
Recovery over 12-48 hours

**Tirofiban**
IV bolus 0.4 microgram/kg/min x 30 min, then 0.1 microgram/kg/min
Renal clearance issues (less than 30 mL/min)

**Eptifibatide**
IV bolus 180 microgram/kg, infusion 2 microgram/kg/min
Return to normal variable, usually within one hour of discontinuation of infusion

**Neuraxial Blockade Management (Spinal/Epidural)**
Please see the ICSI Venous Thromboembolism Prophylaxis guideline.

6.7b. Monitoring and Effect on Laboratory Testing, Parenteral Antiplatelet Agents
In most clinical situations, monitoring of oral antiplatelet agents is not required. There are no laboratory methods that have been shown effective in monitoring antiplatelet activity in patients. In patients where the risk of bleeding is a concern, monitoring may include CBC/platelet count.

6.8b. Treatment of Bleeding/Reversal, Parenteral Antiplatelet Agents
Platelet infusion if bleeding.

6.9b. Patient Education, Parenteral Antiplatelet Agents
If a patient is to receive bridging therapy, the patient or a caregiver must show proficiency in the injection technique and proficiency with adhering to the perioperative schedule.
The subdivision of this section is:

- Implementation Tools and Resources
Implementation Tools and Resources

Criteria for Selecting Resources

The following tools and resources specific to the topic of the guideline were selected by the work group. Each item was reviewed thoroughly by at least one work group member. It is expected that users of these tools will establish the proper copyright prior to their use. The types of criteria the work group used are:

- The content supports the clinical and the implementation recommendations.
- Where possible, the content is supported by evidence-based research.
- The author, source and revision dates for the content is included where possible.
- The content is clear about potential biases and when appropriate conflicts of interests and/or disclaimers are noted where appropriate.

Resources Available to ICSI Members Only

ICSI has knowledge resources that are *only* available to ICSI members (these are indicated with an asterisk in far left-hand column of the Resources Table). In addition to the resources listed in the table, ICSI members have access to a broad range of materials including tool kits on Continuous Quality Improvement processes and Rapid Cycling that can be helpful. To obtain copies of these or other Resources, go to the Education and Quality Improvement page on the ICSI Web site. To access these materials on the Web site, you must be logged in as an ICSI member.

The resources in the table on the next page that are not reserved for ICSI members are available to the public free-of-charge unless otherwise indicated.

*Return to Table of Contents*
# Implementation Tools and Resources Table

<table>
<thead>
<tr>
<th>*</th>
<th>Author/Organization</th>
<th>Title/Description</th>
<th>Audience</th>
<th>Web Sites/Order Information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>American Medical Association Foundation</td>
<td>Site contains downloadable print education materials on cardiovascular and other topics in a wide range of languages.</td>
<td>Health Care Professionals; Patients and Families</td>
<td><a href="http://www.healthinfotranslations.com">http://www.healthinfotranslations.com</a></td>
</tr>
<tr>
<td></td>
<td>American Society of Hematology (ASH)</td>
<td>The &quot;Practice&quot; area of the Web site provides &quot;HIT Quick Reference&quot; pocket guide that summarizes the diagnosis and treatment of heparin-induced thrombocytopenia.</td>
<td>Health Care Professionals</td>
<td><a href="http://www.hematology.org/Practice/">http://www.hematology.org/Practice/</a></td>
</tr>
<tr>
<td></td>
<td>Ansell, Jack</td>
<td>&quot;How-to&quot; manual for establishing anticoagulation clinics</td>
<td>Providers</td>
<td>Managing Oral Anticoagulation Therapy: Clinical and Operational Guidelines</td>
</tr>
<tr>
<td></td>
<td>Anticoagulation Forum</td>
<td>The forum is an organization of anticoagulation clinics across the country. The site is useful for finding clinics in other states and professional meetings relevant to anticoagulation.</td>
<td>Providers</td>
<td><a href="http://www.acforum.org">http://www.acforum.org</a></td>
</tr>
<tr>
<td></td>
<td>Care Clinical Research</td>
<td>Resource on cardiovascular and respiratory diseases. All information is peer-reviewed by a select panel of professionals and lay persons. It includes information specific to antithrombotic therapy.</td>
<td>Providers and patients</td>
<td><a href="http://www.careinternet.net">http://www.careinternet.net</a></td>
</tr>
<tr>
<td></td>
<td>Clot Care</td>
<td>Comprehensive site includes research updates, guidelines, patient education.</td>
<td>Health Care Professionals; Patients and Families</td>
<td><a href="http://www.clotcare.com">http://www.clotcare.com</a></td>
</tr>
<tr>
<td></td>
<td>Clot Connect</td>
<td>National collaborative outreach project of the Blood Clot Outreach Program at the Hemophilia and Thrombosis Center of University North Carolina Chapel Hills. Comprehensive site includes research updates, guidelines, and patient education.</td>
<td>Health Care Professionals; Patients and Families</td>
<td><a href="http://www.clotconnect.org">http://www.clotconnect.org</a></td>
</tr>
</tbody>
</table>

* Available to ICSI members only.

*Return to Table of Contents*
<table>
<thead>
<tr>
<th>*</th>
<th>Author/Organization</th>
<th>Title/Description</th>
<th>Audience</th>
<th>Web Sites/Order Information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Heart Rhythm Society</td>
<td><strong>Heart Rhythm Society:</strong> Comprehensive site includes research updates, guidelines and a reference center for professionals. Patient and public links include a heart information center, electrophysiology referral information and patient stories. Education materials available. Spanish and English.</td>
<td>Health Care Professionals; Patients and Families</td>
<td><a href="http://www.hrsonline.org">http://www.hrsonline.org</a></td>
</tr>
<tr>
<td></td>
<td>Journal of the American Medical Association – Patient Page</td>
<td><strong>JAMA Patient Page:</strong> A public service of the Journal of the American Medical Association. The key objective of JAMA is to promote the science and art of medicine and the betterment of the public health.</td>
<td>Health Care Professionals; Patients and Families</td>
<td><a href="http://www.jama.ama-assn.org/cgi/collection/patient_page">http://www.jama.ama-assn.org/cgi/collection/patient_page</a></td>
</tr>
<tr>
<td>*</td>
<td>Mayo Clinic</td>
<td>&quot;Oral Anticoagulant Therapy: Warfarin®&quot; 2008 Mayo Foundation (MFMER), a 28-page patient education handout addressing basics about clotting and anticoagulants, therapy, includes daily INR/dosing diary for patient to keep records.</td>
<td>Health Care Professionals; Patients and Families</td>
<td>Available only upon request by ICSI member organization.</td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic</td>
<td>Patient education page on what is important prior to taking warfarin orally.</td>
<td>&quot;Warfarin (Oral Route) Before Using&quot;</td>
<td><a href="http://www.mayoclinic.com/health/drug-information/DR602425/DSECTION=before%2Dusing">http://www.mayoclinic.com/health/drug-information/DR602425/DSECTION=before%2Dusing</a></td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic</td>
<td>Patient education page on what is the proper use of warfarin.</td>
<td>&quot;Warfarin (Oral Route) Proper Use&quot;</td>
<td><a href="http://www.mayoclinic.com/health/drug-information/DR602425/DSECTION=proper%2Duse">http://www.mayoclinic.com/health/drug-information/DR602425/DSECTION=proper%2Duse</a></td>
</tr>
<tr>
<td></td>
<td>Mayo Clinic</td>
<td>Patient education page on precautions to consider when taking warfarin orally.</td>
<td>&quot;Warfarin (Oral Route) Precautions&quot;</td>
<td><a href="http://www.mayoclinic.com/health/drug-information/DR602425/DSECTION=precautions%2D">http://www.mayoclinic.com/health/drug-information/DR602425/DSECTION=precautions%2D</a></td>
</tr>
<tr>
<td></td>
<td>National Alliance for Thrombosis and Thrombophilia (NATT)</td>
<td>A patient-led advocacy organization that includes many of the nation’s foremost experts on blood clots and blood clotting disorders.</td>
<td>Patients and Families</td>
<td><a href="http://stoptheclot.org/">http://stoptheclot.org/</a></td>
</tr>
<tr>
<td></td>
<td>National Board of Anticoagulation Providers</td>
<td>The National Certification Board for Anticoagulation Providers is a multidisciplinary group established in 1998 to develop, maintain and foster the certification process in order to optimize care of patients receiving anticoagulation therapy.</td>
<td>Providers</td>
<td><a href="http://www.acforum.org">http://www.acforum.org</a> National Board of Anticoagulation Providers c/o Anticoagulation Forum Boston University Medical Center Room E-113 88 E. Newton St. Boston, MA 02118-2395</td>
</tr>
</tbody>
</table>

* Available to ICSI members only.

Return to Table of Contents
## Implementation Tools and Resources Table

<table>
<thead>
<tr>
<th>*</th>
<th>Author/Organization</th>
<th>Title/Description</th>
<th>Audience</th>
<th>Web Sites/Order Information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>National Institutes of Health (NIH)</td>
<td>Reference Bibliography for the NIH Conference on Dietary Supplements, Coagulation, and Antithrombotic Therapies – a compilation of studies on the effects of vitamins, minerals, fatty acids, herbal/other botanical supplements, other dietary supplements and foods on antithrombotic drugs.</td>
<td>Providers and Patients</td>
<td><a href="http://www.nhlbi.nih.gov/meetings/coagulation">http://www.nhlbi.nih.gov/meetings/coagulation</a></td>
</tr>
</tbody>
</table>

* Available to ICSI members only.

_Return to Table of Contents_
The subdivisions of this section are:

- References
- Appendices
References


Adcock DM, Kressin DC, Marlar RA. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. *Am J Clin Pathol* 1997;107:105-10. (Class B)


Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor X assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. *Pharmacotherapy* 2005;25:157-64. (Class B)


Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin: a randomized, controlled trial. *Ann Intern Med* 2000;133:687-95. (Class B)

*Return to Table of Contents*


Blann A, Hewitt J, Siddiqui F, Bareford D. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. *Br J Haematol* 1999;107:207-09. (Class D)


Castellone DD, Van Cott EM. Laboratory monitoring of new anticoagulants. *Am J Hematol* 2010;85:185-87. (Class Not Assignable)


Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-47. (Class C)


Cornbleet T, Hoit L. Alopecia from coumarin. Arch Dermatol 1957;75:440-41. (Class D)


Dabigatran etexilate (Pradaxa) – a new oral anticoagulant. Med Lett Drugs Ther 2010;52:89-90. (Class Not Assignable)

de Schryver ELLM, Algra A, Donders RCJM, et al. Type of stroke after transient monocular blindness or retinal infarction of presumed arterial origin. J Neurol Neurosurg Psychiatry 2006;77:734-38. (Class D)


Gerhardt A, Zott RB, Stocksclaederland M, Scharf RE. Fondaparinux is an effective alternative anticoagulant in pregnant women with high risk of venous thromboembolism and intolerance to low-molecular-weight heparins and heparinoids. *Thromb Haemost* 2007;97:496-97. (Class A)


Gruel Y, Pouplard C. Post-operative platelet count profile: the most reliable tool for identifying patients with true heparin-induced thrombocytopenia after cardiac surgery. *J Thromb Haemost* 2010;8:27-29. (Class A)
References


Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005;36:1588-93. (Class R)


Jaffer AK. Perioperative management of warfarin and antiplatelet therapy. *Cleveland Clinic J Med* 2009;76:S37-S44. (Class R)


Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. *Am J Med* 1989a;87:144-52. (Class B)


Lip GYH, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? *Am J Med* 2010;123:785-89. (Class M)


NCCLS. Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays: approved guideline – fourth edition. December 2003. (Class R)


Pradaxa. [package insert]. Ridgefield CT; Boehringer Ingelheim Pharmaceuticals, Inc, 2010. (Class Not Assignable)


Reigert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. *Ann Allergy Asthma Immunol* 2002;89:400-06. (Class D)


Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in post-cardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. *J Thromb Haemost* 2010;8:30-36. (Class D)


*Return to Table of Contents*

Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest 2006;130:1390-96. (Class R)


Talmadge DB, Spyropoulos AC. Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome. Pharmacotherapy 2003;23:674-77. (Class D)

Thompson GE. Anticoagulation in the setting of epidural or spinal anesthesia/analgesia. Thromb Haemost 1999;82:913-17. (Class R)


Tryba M, Wedel DJ. Central neuraxial block and low-molecular-weight heparin (enoxaparin): lessons learned from different dosage regimes in two continents. Reg Anesth 1997; 111:100-04. (Class D)


Umlas J, Harken DE. Warfarin-induced alopecia. CUTIS 1988;42:63-64. (Class D)

van Ryn J, Ruehl D, Priepeke H, et al. Reversibility of the anticoagulation effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate. Haematologica 2008;93:148. (Class Not Assignable)


Warkentin TE. An overview of the heparin-induced thrombocytopenia syndrome. *Semin Thromb Hemost* 2004b;30:273-83. (Class R)


Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment and prevention: the seventh ACCP conference on antithrombotic and thrombolytic therapy. *Chest* 2004a;126:311S-37S. (Class R)


Weitz JI, Hirsh J, Samama MM. New anticoagulant drugs: the seventh ACCP conference on antithrombotic and thrombolytic therapy. *Chest* 2004;126:2655-86S. (Class R)


Whitting AM, Bussey Hl, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. *Arch Intern Med* 1998;158:2136-40. (Class C)


*Return to Table of Contents*
Appendix A – Risk Factors for Thromboembolic Event

The European Society of Cardiology atrial fibrillation guidelines recommends the CHA2DS2-VASc scoring system for risk stratification.

CHA2DS2 assigns one point for congestive heart failure [C], high blood pressure [H], age 75 or older [A2], and diabetes [D] and two points for a previous stroke [S2] or transient ischemic attack. The score is broken down into low, intermediate or high in order to assess the annual stroke risk.

<table>
<thead>
<tr>
<th>Risk Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>C Congestive heart failure/Left ventricular dysfunction (1)</td>
</tr>
<tr>
<td>H Hypertension – high blood pressure (1)</td>
</tr>
<tr>
<td>A2 Age ≥ 75 (2)</td>
</tr>
<tr>
<td>D Diabetes mellitus (1)</td>
</tr>
<tr>
<td>S2 Stroke/TIA/TE (thromboembolism) (2)</td>
</tr>
<tr>
<td>V Vascular disease – coronary artery disease (CAD), myocardial infarction (heart attack), peripheral artery disease (PAD), or aortic plaque (1)</td>
</tr>
<tr>
<td>A Age 65-74 (1)</td>
</tr>
<tr>
<td>Sc Sex category – female gender (1)</td>
</tr>
</tbody>
</table>

A CHADS2VASc score = 0 indicates that no antithrombotic therapy would be necessary, while a score of 1 or greater suggests oral anticoagulation may be indicated (European Heart Rhythm Association, 2010 [R]).

Patients defined as intermediate risk by CHADS2 were more likely to have a thromboembolic event (stroke) than those defined as intermediate-risk by CHA2DS2-VASc. Specifically, CHADS2 intermediate-risk patients had 4.75 thromboembolic events per 100 person years at one year, compared to 2.01 for CHA2DS2-VASc intermediate-risk patients. At five years, CHADS2 intermediate-risk patients had 3.70 thromboembolic events per 100 person years, compared to only 1.51 for these defined as intermediate risk by CHA2DS2-VASc.
Appendix B – Risk Factors for Bleeding During Warfarin Therapy

A bleeding risk score (acronym HAS-BLED: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (aged > 65 years), Drugs/alcohol concomitantly has been proposed by Dr. Gregory Lip and associates. The HAS-BLED schema takes into account comorbidities and the fact that patients who have atrial fibrillation are more likely to be taking an anticoagulant and are more likely to be elderly.

<table>
<thead>
<tr>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension (systolic ≥ 160 mmHg) (1)</td>
</tr>
<tr>
<td>Abnormal renal function (1)</td>
</tr>
<tr>
<td>Abnormal liver function (1)</td>
</tr>
<tr>
<td>Age ≥ 65 years (1)</td>
</tr>
<tr>
<td>Stroke in past (1)</td>
</tr>
<tr>
<td>Bleeding (1)</td>
</tr>
<tr>
<td>Labile INRs (1)</td>
</tr>
<tr>
<td>Taking other drugs as well (1)</td>
</tr>
<tr>
<td>Alcohol intake at same time (1)</td>
</tr>
</tbody>
</table>

A score of 3 or greater indicates "high risk," and caution/regular review of the patient is needed (Lip, 2011 [NA]).

Researchers in the EuroHeart Survey on atrial fibrillation determined that using both the CHADS2, the CHADS2VAS (when appropriate), and the HAS-BLED tools could have prevented bleeding in patients who were on oral anticoagulants, as well as strokes in patients who were not.

Return to Table of Contents
ICSI has long had a policy of transparency in declaring potential conflicting and competing interests of all individuals who participate in the development, revision and approval of ICSI guidelines and protocols.

In 2010, the ICSI Conflict of Interest Review Committee was established by the Board of Directors to review all disclosures and make recommendations to the board when steps should be taken to mitigate potential conflicts of interest, including recommendations regarding removal of work group members. This committee has adopted the Institute of Medicine Conflict of Interest standards as outlined in the report, Clinical Practice Guidelines We Can Trust (2011).

Where there are work group members with identified potential conflicts, these are disclosed and discussed at the initial work group meeting. These members are expected to recuse themselves from related discussions or authorship of related recommendations, as directed by the Conflict of Interest committee or requested by the work group.

The complete ICSI Policy regarding Conflicts of Interest is available at http://bit.ly/ICSICOI.

**Funding Source**

The Institute for Clinical Systems Improvement provided the funding for this guideline revision. ICSI is a not for profit, quality improvement organization based in Bloomington, Minnesota. ICSI's work is funded by the annual dues of the member medical groups and five sponsoring health plans in Minnesota and Wisconsin. Individuals on the work group are not paid by ICSI, but are supported by their medical group for this work.

ICSI facilitates and coordinates the guideline development and revision process. ICSI, member medical groups and sponsoring health plans review and provide feedback, but do not have editorial control over the work group. All recommendations are based on the work group's independent evaluation of the evidence.
Disclosure of Potential Conflicts of Interest

**Timinder Biring, MD, Work Group Member**  
Interventional Cardiologist, HealthPartners Medical Group & Regions Hospital  
National, Regional, Local Committee Affiliations: None  
Guideline-Related Activities: None  
Research Grants: None  
Financial/Non-Financial Conflicts of Interest: None

**Stephen Kopecky, MD, Work Group Member**  
Cardiologist, Mayo Clinic  
National, Regional, Local Committee Affiliations: Member, ICSI Committee on Evidence-Based Practice  
Guideline-Related Activities: ICSI Healthy Lifestyles guideline, ICSI Lipid Management guideline and ICSI Heart Failure in Adults guideline  
Research Grants: None  
Financial/Non-Financial Conflicts of Interest: Consultant work for Applied Clinical Intelligence and for Prime Therapeutics

**Kori Krueger, MD, Work Group Member**  
Internal Medicine, Director of Anticoagulation Services and Quality Improvement, Marshfield Clinic  
National, Regional, Local Committee Affiliations: None  
Guideline-Related Activities: ICSI Lipid Management guideline  
Research Grants: None  
Financial/Non-Financial Conflicts of Interest: None

**Tonja Larson, PharmD, BCPS, Work Group Member**  
Clinical Pharmacist, Marshfield Clinic  
National, Regional, Local Committee Affiliations: None  
Guideline-Related Activities: ICSI Diagnosis and Management of Chest Pain and Acute Coronary Syndrome (ACS) guideline and ICSI Venous Thromboembolism Prophylaxis guideline  
Research Grants: None  
Financial/Non-Financial Conflicts of Interest: None

**Seema Maddali, MD, MHA, Work Group Co-Leader**  
Hospitalist Medical Director, Hospitalist Medicine Service, HealthEast Care System  
National, Regional, Local Committee Affiliations: None  
Guideline-Related Activities: ICSI Venous Thromboembolism Diagnosis and Treatment guideline  
Research Grants: None  
Financial/Non-Financial Conflicts of Interest: None

**Melissa Mikelson, RN, BSN, Work Group Member**  
Internal Medicine, Manager, Care Management, Marshfield Clinic  
National, Regional, Local Committee Affiliations: None  
Guideline-Related Activities: None  
Research Grants: None  
Financial/Non-Financial Conflicts of Interest: None

*Return to Table of Contents*
Disclosure of Potential Conflicts of Interest

**Timothy Miley, MD, Work Group Member**
Pathology and Laboratory Medicine, Park Nicollet Health Services
National, Regional, Local Committee Affiliations: American Society of Clinical Pathology, American Society of Hematology for work on the Practice Committee
Guideline-Related Activities: None
Research Grants: None
Financial/Non-Financial Conflicts of Interest: None

**Colleen Morton, MD, Work Group Co-Leader**
Hematology/Oncology, HealthPartners Medical Group & Regions Hospital
National, Regional, Local Committee Affiliations: None
Guideline-Related Activities: ICSI Consensus-Based Statement on Emergency Care of Bleeding and ICSI Venous Thromboembolism Prophylaxis guideline
Research Grants: None
Financial/Non-Financial Conflicts of Interest: None

**Rajiv Pruthi, MBBS, Work Group Member**
Hematology, Mayo Clinic
National, Regional, Local Committee Affiliations: None
Guideline-Related Activities: ICSI Consensus-Based Statement on Emergency Care of Bleeding and ICSI Venous Thromboembolism Prophylaxis guideline
Research Grants: None
Financial/Non-Financial Conflicts of Interest: None

**Anne Schullo-Feulner, PharmD, BCPS, Work Group Member**
Clinical Pharmacist, Park Nicollet Health Services
National, Regional, Local Committee Affiliations: None
Guideline-Related Activities: None
Research Grants: None
Financial/Non-Financial Conflicts of Interest: None

*Return to Table of Contents*
All ICSI documents are available for review during the revision process by member medical groups and sponsors. In addition, all members commit to reviewing specific documents each year. This comprehensive review provides information to the work group for such issues as content update, improving clarity of recommendations, implementation suggestions and more. The specific reviewer comments and the work group responses are available to ICSI members at http://bit.ly/Antithrombo.

Return to Table of Contents
Acknowledgements

We want to thank the following member groups for reviewing and commenting on this document.

Invited Reviewers

During this revision, the following medical groups reviewed this document. The work group would like to thank them for their comments and feedback.

Hennepin County Medical Center, Minneapolis, MN
Marshfield Clinic, Marshfield, WI
Mayo Clinic, Rochester, MN
Minnesota Gastroenterology, St. Paul, MN

Return to Table of Contents
Document History and Development:
Antithrombotic Therapy Supplement

Original Work Group Members

<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leader, Internal Medicine, Park Nicollet Health Services</td>
<td>Bruce Burnett, MD</td>
<td>Park Nicollet Health Services</td>
</tr>
<tr>
<td>Pathology</td>
<td>Timothy Miley, MD</td>
<td>ICSI</td>
</tr>
<tr>
<td>Park Nicollet Health Services</td>
<td>Mark Morrow, MD</td>
<td>Pharmacy</td>
</tr>
<tr>
<td>Internal Medicine</td>
<td>Rajiv Pruthi, MD</td>
<td>Mayo Clinic</td>
</tr>
<tr>
<td>Aspen Medical Group</td>
<td>John Davenport, MD</td>
<td>HealthPartners Medical Group</td>
</tr>
<tr>
<td>Hematology</td>
<td>Stephen Kopecky, MD</td>
<td>Cardiology</td>
</tr>
<tr>
<td>Neurology</td>
<td>Mary Stadick, MA</td>
<td>Facilitator</td>
</tr>
<tr>
<td>Pharmacy</td>
<td>Jill Strykowski, RPh, MS</td>
<td>ICSI</td>
</tr>
<tr>
<td>Nursing</td>
<td>Lori Wurth, RN</td>
<td></td>
</tr>
</tbody>
</table>

Released in February 2013 for Eleventh Edition.
*The next scheduled revision will occur within 24 months.*

Document History

- Incorporated the Dabigatran: Consensus-Based Statement on Emergency Care of Bleeding into the Antithrombotic Therapy Supplement, 2012.

Return to Table of Contents

Contact ICSI at:
8009 34th Avenue South, Suite 1200; Bloomington, MN 55425; (952) 814-7060; (952) 858-9675 (fax)
Online at http://www.ICSI.org

Copyright © 2013 by Institute for Clinical Systems Improvement
ICSI Document Development and Revision Process

Overview

Since 1993, the Institute for Clinical Systems Improvement (ICSI) has developed more than 60 evidence-based health care documents that support best practices for the prevention, diagnosis, treatment or management of a given symptom, disease or condition for patients.

Audience and Intended Use

The information contained in this ICSI Health Care Guideline is intended primarily for health professionals and other expert audiences.

This ICSI Health Care Guideline should not be construed as medical advice or medical opinion related to any specific facts or circumstances. Patients and families are urged to consult a health care professional regarding their own situation and any specific medical questions they may have. In addition, they should seek assistance from a health care professional in interpreting this ICSI Health Care Guideline and applying it in their individual case.

This ICSI Health Care Guideline is designed to assist clinicians by providing an analytical framework for the evaluation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition.

Document Development and Revision Process

The development process is based on a number of long-proven approaches and is continually being revised based on changing community standards. The ICSI staff, in consultation with the work group and a medical librarian, conduct a literature search to identify systematic reviews, randomized clinical trials, meta-analysis, other guidelines, regulatory statements and other pertinent literature. This literature is evaluated based on the GRADE methodology by work group members. When needed, an outside methodologist is consulted.

The work group uses this information to develop or revise clinical flows and algorithms, write recommendations, and identify gaps in the literature. The work group gives consideration to the importance of many issues as they develop the guideline. These considerations include the systems of care in our community and how resources vary, the balance between benefits and harms of interventions, patient and community values, the autonomy of clinicians and patients and more. All decisions made by the work group are done using a consensus process.

ICSI's medical group members and sponsors review each guideline as part of the revision process. They provide comment on the scientific content, recommendations, implementation strategies and barriers to implementation. This feedback is used by and responded to by the work group as part of their revision work. Final review and approval of the guideline is done by ICSI's Committee on Evidence-Based Practice. This committee is made up of practicing clinicians and nurses, drawn from ICSI member medical groups.

Implementation Recommendations and Measures

These are provided to assist medical groups and others to implement the recommendations in the guidelines. Where possible, implementation strategies are included which have been formally evaluated and tested. Measures are included which may be used for quality improvement as well as for outcome reporting. When available, regulatory or publicly reported measures are included.

Document Revision Cycle

Scientific documents are revised every 12-24 months as indicated by changes in clinical practice and literature. Each ICSI staff monitors major peer-reviewed journals every month for the guidelines for which they are responsible. Work group members are also asked to provide any pertinent literature through check-ins with the work group mid-cycle and annually to determine if there have been changes in the evidence significant enough to warrant document revision earlier than scheduled. This process complements the exhaustive literature search that is done on the subject prior to development of the first version of a guideline.

Return to Table of Contents